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ACTH adrenocorticotrophic hormone
AGA appropriate for gestational age
BMI body mass index
cAMP cyclic AMP
CRH corticotropin-releasing hormone
CSF cerebrospinal fluid
DM diabetes mellitus
EPO erythropoietin
FFA free fatty acid
FSH follicle-stimulating hormone
GA gestational age
G-CSF granulocyte colony-stimulating factor
GDM gestational diabetes mellitus
GH growth hormone
HbA1C glycated hemoglobin A fraction
HPA hypothalamus-pituitary-adrenal
HPLC high-pressure liquid chromathography
IGF-I insulin-like growth factor I
IDDM insulin-dependent diabetes mellitus
IL interleukin
IUGR intrauterine growth restriction
JAK janus kinases
LGA large for gestational age
LH luteinizing hormone
9LPS lipopolysaccharide
mRNA messenger RNA
NIDDM non-insulin-dependent diabetes mellitus
OB-gene leptin gene
OB-R leptin receptor
PTH parathyroid hormone
RIA radioimmunoassay
SD standard deviation
SGA small for gestational age
TNF tumor necrosis factor
TRH TSH-releasing hormone
TSH thyroid-stimulating hormone
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1 INTRODUCTION
Leptin hormone, discovered in 1994 (Zhang et al), is produced mainly by adipose tissue.
This hormone has turned out to be involved in multiple processes in human physiology. At
first, interest was focused on the role of leptin in the control of body weight regulation and
satiety (Pelleymounter et al 1995, Halaas et al 1995, Campfield et al 1995). Since then,
the interactions between glucose, insulin, and leptin in various experimental and clincal
conditions, e.g., in diabetes mellitus, have been under intensive study (Malmström et al
1996). It has become evident that leptin takes part in numerous other processes, such as
angiogenesis and reproduction, as well (Cioffi et al 1996) (Table 1).
Gender differences have been a constant finding in leptin studies: In adults and children,
independently of fat mass, females have higher leptin concentrations than males
(Considine et al 1996, Hassink et al 1996), thus reflecting the regulatory effect of other
factors, such as hormones, on leptin metabolism.
Animal studies have shown the presence of high levels of gene expression for leptin, and
for the leptin receptor during fetal development (Hoggard et al 1997a). In humans,
gestational age (Jaquet et al 1998), birth weight (Sivan et al 1997), and type of fetal
growth (Koistinen et al 1997) are important determinants of cord plasma leptin
concentration.
The objectives for this present study were to observe how adaptation to extrauterine life is
reflected in the leptin concentrations of the neonate. We also examined the effect of
hypoxia, of maternal pre-eclampsia, and of diabetes mellitus on fetal leptin concentrations.
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                            Table 1. A brief summary of some of leptin’s major functions.
Leptin secretion Target organ Function(s) Ref human (H)
animal (A)
Adipocyte CNS Controls appetite and body weight Halaas 1995   H     A
Adrenals Decreases production of glucocorticoids Pralong 1998   H     A
Liver Redistributes glucose production,
fetal hematopoiesis
Rosetti 1997,
Cioffi 1996
          A
  H     A
Pancreas beta-cells Reduces insulin secretion Seufert 1999   H
White adipose tissue Reduces glucose uptake Wang 1999          A
Brown adipose tissue Increases glucose uptake Wang 1999          A
Muscle Increases glucose uptake Wang 1999          A
Bone marrow Activates hematopoietic cells, Mikhail 1997,   H    A
T-lymphocyte-mediated immunity Lord 1998          A
Vascular enothelium Stimulates angiogenesis Sierra-Honigman
1998
  H    A
? Initiation of puberty Chehab 1997,
Farooqi 1999
         A
  H
Gastric mucosa ? Bado 1998          A
Trophoblast Placenta/embryo Participates in the development of
placenta/embryo?
Antczak 1997,
Cioffi 1996
         A
  H    A
12
2 REVIEW OF THE LITERATURE
2.1.1  Leptin
Leptin (Greek leptos= thin) is a 16-kD plasma protein synthetized by adipose tissue, and
during pregnancy by the placental tissue (Zhang et al 1994, Masuzaki et al 1998), and at
lower levels by gastric epithelium (Bado et al 1998). The brain has also been suggested to
produce leptin (Wiesner et al 1999).
Leptin is a product of the obese (ob) gene. Mice inheriting mutant copies of this gene from
both parents (ob/ob mice) exhibit marked obesity, low energy expenditure, hyperphagia,
glucose intolerance, insulin resistance, and sterility. Both peripheral and central
exogenous leptin administration to these mice lowers their body weight, body fat
percentage, food intake, and serum concentrations of glucose and insulin; it restores
sterility, and increases body temperature, metabolic rate, and activity levels (Zhang et al
1994, Chehab et al 1996, Pelleymounter et al 1995, Campfield et al 1995, Halaas et al
1995). Similar metabolic and behavioral disturbances are present in mice inheriting two
mutant copies of the diabetes (db) gene (db/db mice). In this case, however,
administration of exogenous leptin does not correct those disturbances (Halaas et al
1995). This is due to a mutation in the db gene which codes for the leptin receptor (OB-R)
necessary for signal transduction (Chen et al 1996).
The ob gene encodes a 4.5-kilobase adipose tissue mRNA with a highly conserved 167-
amino acid open reading frame. The amino-acid sequence is 84% identical between
human and mouse (Zhang et al 1994). In humans, the ob gene has been localized to
chromosome 7q31.3 (Green et al 1995), and to 7q32.1 (Geffroy et al 1995).
The circulating leptin concentrations reflect body fat content in mice and in adult human
beings (Frederich et al 1995, Maffei et al 1995). Leptin is secreted in pulsatile and
circadian fashion with a noctural rise in lean and obese patients, and in patients with non-
insulin-dependent diabetes mellitus (Licinio et al 1997, Sinha et al 1996). The half-life of
the hormone is approximately 25 minutes, and the rate of leptin clearance from plasma is
a mean 1.50 + 0.23 ml/kg/min. Rate of leptin production seems to be directly related to
adiposity. A combination of greater leptin production per unit of body fat, and increased
production from expanded total body fat mass, rather than alterations in leptin clearance,
accounts for the increase in plasma leptin concentrations observed in obese humans
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(Klein et al 1996). Kidneys play a substantial role in leptin removal from plasma by taking
up and degrading the peptide. Such renal leptin uptake may account for approximately
80% of all leptin removal from plasma (Meyer et al 1997). No leptin clearance has been
observed in pulmonary or splanchnic beds (Jensen et al 1999).
In humans, only a few leptin mutations have been found thus far. However, leptin
deficiency has been identified due to a missense leptin gene mutation (Strobel et al 1998).
Patients carrying this mutation present with a clinical picture of morbid obesity,
hypogonadism, sympathetic dysfunction, alterations in growth hormone (GH), and in
parathyroid hormone (PTH)-calcium function, and hyperinsulinemia. They also seem to
have a highly increased risk for childhood mortality due to infections. Despite their obesity,
however, these patients do not have risk factors for cardiovascular disease such as
hypertension, impairment of lipid metabolism, or hyperglycemia (Montaque et al 1997,
Ozata et al 1999).
2.1.2 Leptin receptors (OB-R)
Leptin is recognized by the leptin receptor, the product of the diabetes (db) gene (Tartaglia
et al 1995). The leptin receptor was identified through expression cloning strategy. The
OB-R is a single membrane-spanning receptor related to cytokine receptors such as
interleukin (IL)-6, granulocyte colony-stimulating factor (G-CSF), and leukocyte inhibitory
factor. The OB-R also has the signaling capabilities of IL-6 type cytokine receptors
(Baumann et al 1996). The OB-R has been shown to have at least five splice variants OB-
R(a-e) in the mouse, figure 1, (Chen et al 1996, Lee et al 1996) and four forms in humans
(Cioffi et al 1996). The extracellular forms of these are identical throughout their entire
length. The OB-Rb variant encodes a receptor with a long intracellular domain that is
thought to be essential for intracellular signal transduction (Tartaglia et al 1995). Human
and mice OB-R DNA are 78% identical (Tartaglia et al 1995). The gene coding for OB-R is
located on chromosome 4 in the mouse, 5 in the rat, and 1p in human beings (Chung et al
1996). In humans, an OB-R mutation has been identified leading to extreme obesity in
childhood (Roth et al 1998). OB-Rs signal through tyrosine phophorylation of a class of
transcription factors. Alternative and/or additional signaling pathways of OB-Rb (long form)
involve cytoplasmic protein kinases, (Janus kinases, JAKs), and serine residues
(Considine et al 1996). The obese phenotype of the db/db mouse is generated by
recessive mutations in mice diabetes (db) genes. This db/db mutation leads to loss of the
14
carboxy-terminal region, and to a protein with a truncated cytoplastic domain in the long
form of the OB-R, which renders the OB-R inactive (Chen et al 1996).
Figure 1. OB-R variants in the mouse  (permission for reproduction of this figure is granted by the authors
and Nature, Friedman et al 1998)
In mice, the expression of the OB-R mRNA is the highest in lung and kidney and lower in
liver, skeletal muscle, brain, and heart (Tartaglia et al 1995). In addition, in placenta,
cartilage, and hair follicles high levels of OB-R expression have been observed (Hoggard
et al 1997a). In the murine, the long form is expressed predominantly in the
hypothalamus. Of the peripherial tissues, the long form is expressed at significant levels
only in the medulla of the adrenal, and the inner zone of the medulla of the kidney
(Hoggard et al 1997b). OB-Rb has also been identified in murine and human fetal liver,
and in several hematopoietic cell lines, and in adult human reproductive organs (Cioffi et
al 1996). In humans, the coexpression of long and short isoforms of OB-R has been
detected in brain, bone marrow, fetal liver, and spleen (Gainsford et al 1996). In human
adipose tissue and gastric mucosa, OB-R isoforms have been detected also (Kielar et al
1998, Breidert et al 1999). Recently, the long form of OB-R has been detected in mice and
human lung tissue and in a lung squamous cell line. Experimental data suggest that in
these tissues leptin may act as a growth factor through its specific receptor (Tsuchiya et al
1999). So far, of the tissues tested, only hypothalamus expresses more long form
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transcipt than the most predominant short form (OB-Rs1). The vast majority of OB-R
transcipts detected in various tissues are transcripts encoding short intracellular domain
forms (Tartaglia et al 1997).
Short OB-R forms may play a role in leptin transport and in clearance, but also be a
source of soluble receptor (Tartaglia et al 1997). In fact, OB-Re, which is truncated at the
extracellular domain, has been demonstrated to generate leptin-binding activity in the
circulation (Liu et al 1998).
2.1.3 Leptin-binding proteins
Leptin has been found to bind competitively to at least three serum macromolecules with
molecular masses of ~85, ~176, and ~240 kDa in rodents and ~176 and ~240 kDa in
humans (Houseknecht et al 1996).  Also 80’  or 100-kDa size binding proteins have been
found (Sinha et al 1996). A possible role for the binding proteins is to facilitate the
transport of leptin across the blood-brain barrier to its hypothalamic (or other) site(s) of
action (Houseknecht et al 1996). Leptin-binding proteins may possibly be soluble forms of
leptin receptors. This feature is typical of a number of members of the cytokine family
(Muller-Newen et al 1996).
In nonobese humans and mice, a significant portion of endogenous leptin is bound. With
increasing severity of obesity and increasing circulating leptin levels, leptin "spills over"
into the circulating free, presumeably bioactive protein, pool. The percentage of free leptin
is also stongly related to the degree of obesity (Houseknecht et al 1996, Sinha et al 1996).
That changes in free leptin are rapid and significant during fasting and refeeding suggests
that bound and free leptin behave as different compartments in such physiological
alterations (Sinha et al 1996). During pregnancy, no significant difference in free or bound
leptin levels exists between normal and insulin-dependent diabetic subjects, but the latter
have significantly higher soluble leptin receptor levels (Lewandowski et al 1999).
2.1.4 Leptin and cytokines
Leptin, which is thought to be ancestrally related to the cytokines (Bornstein et al 1998), is
suggested to participate in the modulation of the immune and cytokine response to
inflammation. Indeed, the full-length leptin receptor has the signaling capabilities of IL-6-
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type cytokine receptors (Baumann et al 1996). In mice, the administration of tumor
necrosis factor (TNF), IL-1, and leukocyte inhibitory factor, but not IL-10, IL-4, or IL-2,
produces a prompt and dose-dependent increase in serum leptin levels and leptin mRNA
expression in fat. However, after administration of Escherichia coli lipopolysaccharide
(LPS), leptin levels rose (Sarraf et al 1997). IL-1 is essential for leptin induction by LPS,
but IL-6 is not (Faggioni et al 1998). Sensitivity to LPS-induced mortality is significantly
greater in ob/ob mice; however, this sensitivity was reversed after treatment with leptin
(Faggioni et al 1999). Ob/ob and db/db mice, as well as normal mice treated with leptin
receptor antagonist, exhibit increased sensitivity to the lethal effect of TNF. Exogenous
leptin affords protection to TNF in ob/ob, but not in other mice (Takahashi et al 1999). In
vitro, both in mice and men, the TNF produced by adipocytes can inhibit leptin production
through the TNF-type I receptor, suggesting the presence of autocrine or paracrine
regulation of leptin in mouse and human adipose tissue (Yamaguchi et al 1998).
Interestingly, in healthy humans in vivo, subcutaneous abdominal adipose tissue has been
shown to release IL-6, but not TNF (Mohamed-Ali et al 1997).
 In diabetic as well as in healthy humans, TNF levels are independently associated with
circulating leptin levels (Mantzoros et al 1997). Repeated TNF infusions have resulted in
an increase in serum leptin levels, levels which return to baseline within 24 h after
cessation of TNF infusions, suggesting that leptin levels are under the control of TNF
(Zumbach et al 1997). Equally, IL-1 infusions have been shown to increase serum leptin
concentrations in a dose-dependent fashion. However, after prolonged treatment,
tachyphylaxis of the leptin response appeared (Janik et al 1997).
 In survivors of sepsis, there exists a negative relation beween IL-6 and leptin. This is of
potential importance, as high IL-6 levels have been associated with poor outcome in
critically ill patients, and relatively low leptin levels may impair sympathetic system and
immune functions (Torpy et al 1998).
Both ob/ob and db/db mice have impaired T-lymphocyte immunity. Leptin has been found
to increase T-helper lymphocyte 1 and suppress T-helper lymphocyte 2 cytokine
production. Administration of leptin also reversed the immunosuppressive effects of acute
starvation. These findings suggest a role for leptin in linking nutritional status to cognate
cellular function, and provide a molecular mechanism to account for the immune
dysfunction observed in starvation (Lord et al 1998).
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2.2.1 Leptin and the central nervous system: leptin resistance, control of appetite,
and body weight
In humans, cerebrospinal fluid (CSF) and plasma leptin concentrations correlate in a
nonlinear manner, with their ratio being lower in persons with higher plasma leptin levels
or body mass index  (BMI) (weight kg/ length m2) (Caro et al 1996, Schawartz et al 1996).
Leptin enters the brain by a saturable system (Caro et al 1996, Schwartz et al 1996,
Banks et al 1996) independent of insulin (Banks et al 1996). The OB-R-mediated transport
of leptin into the central nervous system through the blood-brain barrier takes place in the
choroid plexus (Tartaglia et al 1995) and in brain microvessels (Golden et al 1997,
Bjorbaek et al 1998). The most abundant OB-R isoform in both locations is the short
isoform, OB-Ra (Boado et al 1998, Bjorbaek et al 1998). It has been postulated that leptin
can also enter the central nervous system independently of leptin receptors (Wu-Peng et
al 1997). The saturable mechanism mediating CSF leptin transport, and reduced
efficiency of brain leptin delivery in hyperleptinemic obese patients, may provide a
mechanism for the leptin resistance observed in such individuals (Schwartz et al 1996).
However, the basis for leptin resistance in humans is unknown, and data from animal
studies indicate that this condition is likely to be heterogenous (Friedman et al 1998).
Leptin receptors have been found in several hypothalamic nuclei (Mercer et al 1996, Fei et
al 1997). Each of these nuclei is important in regulating body weight by expressing one or
more neuropeptides and neurotransmitters that regulate food intake and/or body weight
(Spiegelman et al 1996). Of the hypothalamic nuclei, the lateral modulates activity of the
parasympathetic and ventromedial sympathetic nervous systems (Friedman et al 1998).
Neuropeptide Y is the most potent orexigenic (appetite-increasing) agent when
administered intrathecally. In other respects, also, its functions are opposite to those of
leptin: decreased energy expenditure and increased lipogenesis (Woods et al 1998)
Neuropeptide Y mRNA is increased in ob/ob mice and decreases after leptin treatment
(Stephens et al 1995).
Leptin may stimulate the action of the anorexogenic (appetite-decreasing) agents and
antagonize the orexigenic effects of others. Thus, during starvation, leptin levels fall, and
activate a behavioral and metabolic response that is adaptive when food is unavailable.
Weight gain increases plasma leptin concentration and elicts a different response, leading
to a state of negative energy balance. It is not known whether the same or different
neurons respond to increasing and decreasing leptin levels (Friedman at al 1998).
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Moreover, different thresholds exist for several of leptin's actions (Ioffe et al 1998). Recent
animal studies suggest, however, that the dose-dependent effects of leptin on
hypothalamic target neurons at the level of mRNA expression are variable, with some
neurons, like neuropeptide Y, responding across a broad dose-range, and others showing
a limited response within the low range. This further suggests that the central targets of
leptin that mediate the transition from starvation to the fed state may be distinct from those
that mediate the response to overfeeding and obesity (Ahima et al 1999).
2.3.1 Leptin and interactions between glucose and insulin metabolism
In humans, plasma insulin does not acutely regulate leptin production in healthy
individuals or in patients with insulin-dependent diabetes mellitus (IDDM) or non-insulin-
dependent diabetes mellitus (NIDDM) (Malmström et al 1996, Tuominen et al 1997, Vidal
et al 1996). However, after four hours of supraphysiological hyperinsulinemia, leptin
concentrations increase (Utriainen et al 1996). During prolonged exposure to insulin in
vitro (abdominal adipocytes), and in vivo, increased leptin production can also be
demonstrated in both healthy individuals and in NIDDM patients (Kolaczynski et al 1996a,
Malmström et al 1996), whereas hyperglycemia or high plasma free fatty acid (FFA) levels
have no effect on leptin release (Boden et al 1997). The circadian rhythm of leptin
correlates inversely with the 24-h cycle of insulin sensitivity (Boden et al 1997). Chronic
hyperinsulinemia in insulin-resistant men has been found to be associated with higher
plasma leptin levels independent of body fat mass (Segal et al 1996), whereas this
association has not been found in postmenopausal women (Larsson et al 1996). Insulin
resistance is defined as an impaired ability of insulin to stimulate the uptake and disposal
of glucose by muscle (Reaven et al 1996).
In most studies leptin has been shown to suppress insulin secretion from human
pancreatic beta-cells (Seuffert et al 1999). Conversely, stimulatory effects of insulin have
been demonstrated on leptin production taking place in adipocytes (Seufert et al 1999).
During fasting, leptin concentrations decrease. However, if insulin and glucose levels are
maintained at basal levels, no change occurs in leptin levels during fasting, and
hyperketonemia does not affect leptin concentrations (Boden et al 1996, Kolaczynski et al
1996b). On the other hand, short-term overfeeding is associated with moderate elevation
in circulating leptin levels, and long-term overfeeding, resulting in weight gain, causes a
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rise in leptin concentrations paralleling the increase in percentage of body fat (Kolaczynski
et al 1996c).
In rat adipocytes, leptin mRNA levels rise after food intake, and after insulin injection
(Saladin et al 1995). However, the increased leptin secretion over 96 hours caused by
insulin is more closely related to the amount of glucose taken up by the adipocytes than to
insulin concentration per se, suggesting a role for glucose transport or metabolism, or
both, in regulating leptin secretion (Mueller et al 1998). The insulin-stimulated release of
leptin from adipocytes is blocked by norepinephrine or by a selective beta 3-adrenergic
receptor agonist, suggesting that the beta 3-adrenergic receptor plays a central role in
regulating the release of leptin from the adipocyte (Gettys et al 1996).
Leptin also affects the intrahepatic glucose fluxes: in mice, the administration of leptin
after feeding results in marked suppression of glycogenolysis, whereas the percentage
contribution of gluconeogenesis to hepatic glucose production increases (Rosetti et al
1997). That similar effects, with much lower doses of leptin, can be achieved with
intracerebroventricular leptin admistration, suggests that regulation of hepatic glucose
fluxes may be mediated via its central receptors (Liu et al 1998).
In addition, leptin has differential, tissue-specific effects on glucose and oxygen utilization.
Leptin increases glucose uptake and utilization in brown adipose tissue and muscle, but
decreases these in white adipose tissue. These differences are at least partly due to the
enhancing effect of leptin on the expression of glucose transporter protein-4 and mRNA in
brown adipose tissue, whereas leptin decreases their expression in white adipose tissue.
Leptin also increases the oxygen consumption in brown adipose tissue (Wang et al 1999).
This increase may also result from the stimulatory effect of leptin on the levels of
uncoupling proteins or by preventing their fall in brown adipose tissue from occurring at
times of reduced energy intake. These effects are suggested to be mediated via
hypothalamic leptin receptors, because the effects of i.v. and intracerebroventricularly
administered leptin are qualitatively similar (Rouru et al 1999). These mechanisms may be
important in leptin’s participation in the regulation of body weight and energy expenditure.
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2.3.2 Leptin and interactions between other hormones
The ob/ob mutant mice, in addition to being obese, are hyperinsulinemic and
hypercorticosteronic (Garthwaite et al 1980). A similar phenotype is observed in db/db
mice or fa/fa rats suffering from mutations in the leptin receptor (Chen et al 1996, Chua et
al 1996). Chronic leptin replacement in ob/ob mice, but not in db/db mice, corrects this
hypercorticosteronemia (Stephens et al 1995). In animal studies, mainly mouse and rat,
leptin, glucocorticoids, and the hypothalamus-pituitary-adrenal (HPA) axis have recently
been found to form a bi-directional circuit between HPA axis function and adipose tissue
metabolism (Heiman et al 1997, Spinedi et al 1997).
In ob/ob rat adipocytes, administration of glucocorticoids increases both leptin mRNA
levels and secreted leptin levels in vitro, and, in these animals, beta-adrenergic agonists
which increase intracellular cyclic AMP (cAMP) directly decrease leptin mRNA expression
(Slieker et al 1996). Either the lack of circulating glucocorticoid or the increased plasma
adrenocorticotrophic hormone (ACTH) concentrations, or both, are responsible for
decreasing leptin output, whereas decreased plasma ACTH concentrations allow an
increase in leptin secretion into the circulation (Spinedi at al 1998). In hypothalamic cells
in the rat, leptin inhibits secretion of corticotropin-releasing hormone (CRH) in a dose-
dependent manner. However, leptin does not alter secretion of ACTH from rat pituitary
cells. Leptin's ability to inhibit CRH release is the likely explanation for its ability to inhibit
activation of the HPA axis in response to stress (Heiman et al 1997). Interestingly, in
bovine adrenocortical cells, leptin has also been demonstrated to inhibit adrenal
steroidogenesis. This regulation has been suggested to take place at the transcriptional
level (Bornstein et al 1997). In rat as well in human adrenocortical cells, leptin inhibits
stimulated corticosterone secretion in a dose-dependent manner. These effects of leptin in
adrenal cells are likely mediated by the long isoform of the leptin receptor (OB-R),
because it is expressed in the adrenal tissue, and leptin has no inhibitory effect in adrenal
glands obtained from db/db mice (Pralong et al 1998).
In humans, treatment with either dexamethasone or corticosteroids increases plasma
leptin concentrations (Kolaczynski et al 1997, Wolthers et al 1998). In patients with
Cushing's syndrome, leptin levels are elevated in comparison with those in healthy
controls even after adjustment for body fat; after treatment they decline concomitantly with
corticosterone concentrations (Masuzaki at al 1997). In contrast to these findings, Licinio
found no change in pre- and post-operative leptin values in patients with Cushing's
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disease, despite a 15-fold decline in ACTH levels. They also reported that rapid
fluctuations in plasma leptin levels are inversely related to pituitary-adrenal function
(Licinio et al 1997). In human adult survivors of acute sepsis, both leptin and cortisol levels
are significantly higher than in controls (Bornstein et al 1998). Thus, there exists some
discrepancy as  to the effects of glucocorticoids on leptin concentrations in humans (Torpy
et al 1998).
Thyroid hormone status influences leptin plasma concentration. During hypothyroidism,
decreased leptin levels appear, whereas during hyperthyroidism, leptin levels remain
unchanged (Valcavi et al 1997). During protracted critical illness, treatment with TSH-
releasing hormone (TRH) -  which usually elicits a rise in thyroid hormones does not affect
circulating leptin levels (Van den Berghe et al 1998).
Although in bovine adipose tissue, GH administration alone does not affect leptin gene
expression, GH, in combination with high concentrations of dexamethasone or insulin, or
both, attenuates the ability of insulin or dexamethasone to stimulate leptin expression in
vitro. In vivo, in castrated male cattle, however, GH treatment increases adipose tissue
leptin and insulin-like growth factor I (IGF-I) mRNA concentrations (Houseknecht et al
2000).
 In healthy humans, GH administration has no effect on serum leptin concentrations
(Wolthers et al 1998). In GH deficiency, serum leptin is elevated, and it is lowered by GH
substitution (Nyström et al 1997).
The sexual diphormism in leptin concentrations observed in humans and rodents is likely
due to differences in concentrations of testosterone and other sex hormones.
Testosterone has been shown to downregulate leptin production at both the protein and
mRNA levels in human adipocytes (Wabitsch et al 1997). Male patients with idiopathic
hypogonadotropic hypogonadism and Klinefelter's syndrome have significantly higher
leptin levels than do normal men. During testosterone or gonadotopin treatment for three
months leptin levels fail to change significantly (Ozata et al 1998). In adult males, leptin
correlates negatively with testosterone and positively with estradiol, and also positively in
adult females with fasting plasma estradiol, independently of age, amount of body fat, and
waist/hip ratio (Paolisso et al 1998). Administration of testosterone to healthy young men
suppresses serum leptin levels significantly (Luukkaa et al 1998). However, in some
studies, such correlations of testosterone with leptin levels have become non-significant
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after adjustment for BMI (Haffner et al 1997). In male-to-female transsexuals, introduction
of anti-androgen and estradiol treatment leads to significant increase in serum leptin
concentrations. Conversely, testosterone treatment of females reduces leptin levels.
These results indicate that in the regulation of serum leptin levels sex steroid hormones
play an important role (Elbers et al 1997).
2.3.3 Leptin during childhood and puberty
Levels of circulating soluble leptin receptor are low at birth, high in prepubertal children;
they fall throughout puberty, and remain stable during adult life. The highest levels of
soluble leptin receptors occur during the years when the pituitary gonadal axis is
quiescent. Thus, these changes in concentrations of soluble leptin receptor could explain
how leptin regulates puberty (Quinton et al 1999).
Prepubertal girls have higher plasma leptin concentrations than boys independent of
adiposity, according to some (Hassink et al 1996, Garcia-Mayor et al 1997), but not all
studies (Arslanian et al 1998). BMI correlates strongly with serum leptin concentrations
(Hassink et al 1996, Nagy et al 1997). However, in prepubertal children this gender
difference in leptin concentrations seems to disappear when fat distribution is taken into
account (intra-abdominal vs. subcutaneous abdominal) (Nagy et al 1997). In children as in
adults, subcutanous fat correlates much more strongly than does visceral fat with serum
leptin concentrations (Caprio et al 1996). No gender difference exists in CSF leptin levels,
but the CSF/plasma leptin ratio is lower in girls than in boys. CSF/plasma ratios for lean
children are higher than those for obese children (Wiedenhoft et al 1999). No effect of
ethnicity on leptin concentrations has been evident (Hassink et al 1996, Nagy et al 1997).
In healthy mice, leptin treatment results in earlier maturation of the reproductive tract,
leading to earlier reproduction (Chehab et al 1997). In the ob/ob mouse, puberty does not
progress until exogenous leptin is administered (Chehab et al 1996). An analogous
pattern seems to exist in the few known leptin-deficent human patients: a 22-year-old
adult male showed clinical features of hypogonadism and had not yet entered puberty,
and a 34-year-old woman showed primary amenorrhoea (Strobel et al 1998).
A 9-year-old prepubertal girl with congenital leptin deficiency was treated with daily
subcutaneous recombinant methionyl leptin injections. Her bone age before treatment was
12.5 years, height 140 cm, and weight 94.4 kilograms. After one week of treatment her
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marked hyperphagia normalized. The patient lost weight within two weeks after the
initiation of leptin treatment; 95% of her weight loss was accounted for body fat. At the
beginning of the treatment she was normoglycemic but had high plasma insulin while
fasting. Cholesterol and triglyceride concentrations as well as her thyroid, adrenal, and
somatotrophic function, as indicated by insulin-like growth factor I, and basal metabolic
rate when expressed per unit of lean mass remained normal throughout the one-year
treatment. At baseline the patient’s serum concentrations of estradiol, follicle-stimulating
hormone (FSH), and luteinizing hormone (LH) were consistent with her prepubertal status.
However, after 12 months of leptin treatment, her noctural pattern of gonadotropin
secretion was pulsatile, which is consistent with early puberty. Whether adequate serum
leptin concentrations are required for normal pubertal development or, alternatively,
whether leptin plays an active role in the initiation of puberty is unknown (Farooqi et al
1999).
In normal girls from 5 to 15 years of age, and in boys until the age of 10 years, leptin
concentrations increase in parallel with body weight. In girls, onset of puberty is marked by
an increase in leptin that is first followed by an increase in FSH, and later by increases in
LH and estradiol. A similar pattern occurs in boys, despite the fact that leptin concentration
drops after 10 years of age when testosterone rises (Garcia-Mayor et al   1997, Mantzoros
et al 1997). The analysis of changes in leptin concentrations according to pubertal stages
in girls showed steadily increasing leptin concentrations from Tanner stage 1
(=prepubertal) to 5 (=adult), whereas in boys, leptin levels were highest at Tanner stage 2,
and declined thereafter (Blum et al 1997, Wabitsch et al 1997, Carlsson et al 1997). In
boys, testosterone accounted for 10% and BMI for 52% of the variation in leptin (Blum et
al 1997). Moreover, at Tanner stages G3-G5, leptin is related negatively to testicular
volume (Clayton et al 1997).
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2.4 Leptin concentrations during human pregnancy and the perinatal
period
2.4.1 Leptin plasma concentrations during human pregnancy: in normal, diabetic,
and pre-eclamptic women
Maternal serum leptin concentrations increase progressively up to 2-to-3-fold during the
first two trimesters, followed by a slight decline thereafter. Until the second trimester,
maternal BMI and weight correlate with serum leptin levels (Hardie et al 1997, Tam et al
1998, Tamura et al 1998). Maternal serum leptin levels do not correlate with infants’s birth
weight (Schubring et al 1997, Tam et al 1998, Tamura et al 1998). A correlation between
maternal and cord plasma leptin levels is shown in some (Tamura et al 1998, Varvarigou
et al 1999), but not all studies (Schubring et al 1997, Hassink et al 1997, Lepercq et al
1997, Helland et al 1998, McCarthy et al 1999). The lack of correlation between maternal
and cord leptin concentrations in normal pregnancy, as observed in most studies, is
consistent with a noncommunicating, 2-compartment model of fetoplacental leptin
regulation (McCarthy et al 1999). Gender of the fetus may modify the increase in maternal
leptin levels from 18 to 35 weeks of pregnancy: increase in leptin levels was not significant
in women carrying male fetuses (Helland et al 1998).
No significant difference exists between type I diabetes mellitus (DM) pregnant mothers
and healthy mothers in total, and in free and bound leptin levels (Lepercq et al 1997,
Stock et al 1998, Lewandowski et al 1999). However, type I DM mothers have significantly
higher soluble leptin receptor levels. This may implicate the development of the leptin
resistance seen in type I DM mothers during pregnancy (Lewandowski et al 1999).
During pre-eclampsia, increased leptin concentrations occur in maternal plasma (Mise et
al 1998, McCarthy et al 1999, Kokot et al 1999, Sattar et al 1998, Laivuori et al 2000).
Maternal and cord plasma leptin concentrations correlate during pre-eclampsia; increased
delivery of leptin from the placenta to the mother may result in increased maternal free
fatty acids and glucose for the fetus and thus partially compensate for the nutritional
deprivation caused by this reduction in placental perfusion (McCarthy et al 1999). During
normotensive and pre-eclamptic pregnancy, circulating leptin levels correlate with fasting
insulin levels. However, during the puerperal period, circulating leptin concentrations and
insulin sensitivity correlate only in women with prior pre-eclampsia. Therefore,
hyperleptinemia observed in pre-eclamptic women may be part of the insulin-resistance
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syndrome. During pregnancy, placental leptin production may thus interfere with the
correlation between leptin and insulin (Laivuori et al 2000). It has also been postulated
that during pre-eclampsia, hypoxic conditions in the placenta augment trophoblast cells’
production of increased amounts of leptin (Mise et al 1998).
2.4.2 The placenta as a source of leptin
The placenta has been shown to produce leptin (Masuzaki et al 1997). Accordingly, leptin
mRNA has been found in placental tissue (Hassink et al 1997, Lepercq et al 1998, Mise et
al 1998). In the placentas of diabetic mothers requiring insulin therapy are higher levels of
leptin mRNA than for nondiabetic women (Lepercq et al 1998). In the mouse and human
placenta, OB-R mRNA has been detected in trophoblasts (Henson et al 1998, Yamaguchi
et al 1998); during pregnancy its concentrations increase, and cAMP can reduce its
expression (Yamaguchi et al 1998). In human pregnancies, both in early gestation, at 7 to
14 weeks, and at term, placental leptin and OB-R transcipts have been identified in
trophoblasts. No changes are apparent for OB-R mRNA concentrations, but leptin mRNA
concentrations are significantly lower at term than in early pregnancy (Henson et al 1998).
A higher leptin concentration in umbilical vein than in umbilical artery plasma suggests that
the placenta may be a site for leptin production (Yura et al 1998). This phenomenon has
not, however, been found in all studies (Marchini et al 1998, Ertl et al 1999), and the
opposite finding has been presented by Schubring et al 1997. However, a repeated finding
in most studies is a significant correlation between placental weight and cord plasma leptin
concentration (Koistinen et al 1997, Gomez et al 1999, Varvarigou et al 1999), with few
exceptions (Yura et al 1998). A rapid postpartal decline in leptin plasma concentrations of
the mother and the newborn infant further supports the theory of the placenta as a source
of leptin (Mise et al 1998, McCarthy et al 1998, Helland et al 1999, Yura et al 1998,
Matsuda et al 1999, Harigaya et al 1999, Ertl et al 1999).
2.4.3 Effect of maternal diabetes mellitus, pre-eclampsia, type of birth, and maternal
smoking on leptin concentrations in cord plasma
Newborn infants of diabetic mothers have higher cord plasma leptin concentrations than
do infants of nondiabetic mothers. In addition, cord plasma leptin and the glycated
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hemoglobin A fraction (HbA1C) of the infant have been shown to correlate significantly
(Shekhawat et al 1998). In a study by Persson et al (1999) infants both of mothers with
type I DM and with gestational diabetes mellitus (GDM) had 3- to 4-fold higher cord leptin
concentrations  than did controls, although the HbA1C level fell within the normal range in
type I DM and healthy mothers. Maffei et al (1998) found that infants of type I DM mothers
had higher cord plasma leptin, C-peptide, and insulin concentrations than did infants of
healthy or GDM mothers; the mothers with type I DM had higher HbA1C than did control
or GDM mothers. Gross et al (1998) found, as well, that infants of diabetic mothers had
higher cord plasma leptin concentrations than those of nondiabetic mothers. This group of
diabetic mothers comprised both type I DM, GDM, and insulin-treated GDM mothers.
However, these groups were not compared with one another, due to the small number of
patients in each group. Lepercq et al (1998) found in diabetic (both type I DM and GDM)
mothers higher insulin levels than in control mothers, and the infants of these diabetic
mothers also showed higher cord plasma concentrations of insulin and leptin, but not of
glucose.
During pre-eclampsia, increased leptin concentrations in cord blood are observed in some
(Kokot et al 1999), but not in other studies (McCarthy et al 1999). Thus far, this
phenomenon has received scant attention.
Vaginal delivery or delivery by Cesarean section has been not found to affect cord leptin
concentrations in term infants (Marchini et al 1998, Tarquini et al 1999). Maternal smoking
has been attributed to elevated cord plasma leptin concentrations in some (Mantzoros et
al 1997), but not in all studies (Helland et al 1998).
2.4.4 Leptin and fetal development
The leptin hormone-deficient ob/ob mice are sterile; their fertility, however, is restored by
administration of leptin (Chebab et al 1996). In such mice, despite withdrawal of leptin
replacement therapy at a very early stage of gestation, 0.5 days postcoitally, pregnancy
continues to term, and pups are delivered normally without signs of deformities (Mounzih
et al 1998).
Leptin can be detected in human and mice oocytes, and in embryos at the preimplantation
stage. At the morula stage, leptin-containing cells are distributed in the outer portion which
later forms the trophoblast (Antczak et al 1997). Leptin hormone is present in the yolk-sac
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fluid, and stimulates the proliferation of yolk-sac and fetal liver cells in a dose-dependent
fashion (Cioffi et al 1996, Mikhail et al 1997). Leptin directly stimulates hematopoietic
precursors: The hormone alone can increase the number of macrophage and granulocyte
colonies, and leptin and erythropoietin act synergistically to increase erythroid
development. These results suggest that leptin may have an important unanticipated role
in the development of the hematopoietic and immune systems (Mikhail et al 1997). In
addition, in the murine fetal liver, OB-R expression is significant at the time that the liver is
the major hematopoietic organ. Additionally, in both mice and human beings, OB-R is
expressed in the fetal liver, and at significant levels in many myeloid, and at least in some
lymphoid, cell lines (Cioffi et al 1996).
OB-R is expressed in human vasculature and in primary cultures of human endothelial
cells. In vivo and in vitro assays have revealed that leptin has angiogenic activity. Leptin
may thus spur blood-vessel growth in the maturing egg and early embryo (Sierra-
Honigman et al 1998, Barinaga et al 1998).
During murine fetal development, high levels of the leptin gene, leptin-receptor, and
receptor variants have been observed in the placenta, fetal cartilage/bone, and hair
follicles. Receptor expression has also been detected in the lung, leptomeninges and
choroid plexus of the fetal brain. Leptin, leptin-receptor, and receptor variant mRNAs are
expressed more densely in the placenta than in fetal tissues. The expression of leptin-
receptor mRNA and leptin protein in the same tissue, but in different cell populations,
indicates that in the fetus, leptin may function in an autocrine or paracrine manner
(Hoggard et al 1997a).
2.4.5 Development of fetal adipose tissue
Adipose tissue clearly differentiates around a rich bed of capillaries, and for adipose tissue
to develop, there must be a sluggish blood supply. Capillary endothelium itself may give
rise to adipocytes. However, it is not yet certain from which cells adipocytes develop,
although they temporarily exhibit structural similarities to fibroblasts and endothelial cells.
In the embryo, the precursor cells of brown and white adipocytes appear to acquire their
distinctive cytogenic properties at a very early stage. In vivo and in vitro observations
suggest that the brown adipose precursor cell is morphogenetically distinct from the white
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adipose precursor cell on the one hand, and from the fibroblasts and endothelial cells on
the other (Ryan 1992, Nnodim 1987).
In early fetal development, the rate of fetal fat synthesis is very low and is probably limited
to synthesis of structural lipids of cellular membranes and other structures (Widdowson et
al 1951). Given that lipid metabolism is perfectly developed in early pregnancy, fetal lipid
composition remains unchanged from 6 to 32 weeks of gestation (Carrera 1998).
During the second half of gestation, fetal fat synthesis and storage rates increase
exponentially (Carrera 1998). In relation to fat distribution, an increase in body fat of 10 to
80 g occurs between day 200 and birth, whereas subcutaneous fat shows an exponential
increase, from 20 to 350 g during the same period. Subcutaneous fat-wasting
characterizes fetal growth retardation, and, starting from day 200 and coinciding with an
increase in fat synthesis, a marked increase in energy of fat origin appears (100 kcal/day)
(Carrera 1998).
Brown adipose tissue in fetuses at 25 to 27 weeks of gestation is fairly well differentiated
and thermogenetically active (Zancanaro et al 1995). In most small for gestational age
(SGA; birth weight < -2 SD) infants the development of brown fat corresponds to that of
AGA infants of the same postconceptional age (Moragas et al 1983).
2.4.6 Leptin and fetal growth
Leptin is present in human cord blood as early as at 18 weeks of gestation (Jaquet et al
1998), and leptin concentrations increase progressively throughout gestation from 1.30 +
0.53 ng/ml at 30 weeks of gestation to 7.98 + 4.96 ng/ml at term (Gomez et al 1999). After
34 to 35 weeks of gestation, a rapid increase in cord plasma leptin concentration is
evident (Jaquet et al 1998, Harigaya et al 1997, Matsuda et al 1999), and gestational age
(GA) has been shown to correlate with cord plasma leptin concentrations from that point
onward (Matsuda et al 1997, Jaquet et al 1998). Leptin concentrations in preterm and
term infants increase concomitantly with birth weight (Shekhawat et al 1998, Jaquet et al
1998, Sivan et al 1997, Schubring et al 1997, Hassink et al 1997, Koistinen et al 1997,
Harigaya et al 1997, Ertl et al 1999, Gomez et al 1999). Genetic inheritance may also
influence cord plasma leptin concentrations, because it has been demonstrated that cord
plasma leptin concentration is elevated in the presence of a family history of obesity on
the paternal side, but not on the maternal side; also in the same study, higher leptin
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concentrations were observed in those infants born in spring and summer than in fall, and
higher in infants born before noon (Tarquini et al 1999).
 In term infants, type of fetal growth has been shown to influence cord plasma leptin
concentrations: large for gestational age (LGA; birth weight > 2 SD) infants have higher
leptin concentrations than appropriate for gestational age (AGA) or SGA infants (Sivan et
al 1997, Koistinen et al 1997, Marchini et al 1998, Jaquet et al 1998, Harigaya et al 1997,
Cinaz et al 1999, Varvarigou et al 1999). Moreover, fetal growth expressed as relative birth
weight (weight SD) has been shown to correlate with cord plasma leptin concentration
(Matsuda et al 1997).
The amount of adipose tissue of an infant has been estimated in different studies by
different indirect indices such as weight/length ratio (Matsuda et al 1999), body mass
index (BMI) (kg/m2) (Hassink et al 1997, Jaquet et al 1998, Marchini et al 1998, Gomez et
al 1999, Ertl et al 1999), ponderal index (kg/m3) (Harigaya et al 1997, Lepercq et al 1999,
Tarquini et al 1999, Varvarigou et al 1999, Ong et al 1999), or Kaup index (g/cm2x10)
(Matsuda et al 1997). Cord blood leptin concentrations have correlated with these
parameters in most studies, but not in all (Tarquini et al 1999).
The ponderal index has been shown to differentiate fetal overgrowth into symmetric and
asymmetric subtypes, and show that infants with the asymmetric type of overgrowth have
the higher cord plasma insulin and leptin concentrations (Lepercq et al 1999). In addition,
fetal fat mass has been approximated by measurements of triceps skinfold thickness or
midarm circumference (Hassink et al 1997), or by subscapular, biceps, and triceps
skinfold thickness (Schubring et al 1999). These, too, have correlated with cord plasma
leptin concentrations, and showed that skinfold thickness and weight account for
approximately 35 to 70% of the variation in cord plasma leptin levels (Hassink et al 1997).
2.4.7 Hormonal and metabolic adaptation of the infant to extrauterine life
Fetal adaptation from intrauterine to extrauterine life requires hormonal and metabolic
changes to take place prior to birth, at birth, and within the first days of extrauterine life.
Plasma levels of CRH are markedly elevated during the perinatal period, resulting in a
surge of ACTH secretion (Winter 1992). Part of the increase in CRH secretion is due to
placental production of CRH into the fetoplacental circulation, especially during pre-
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eclampsia (Laatikainen et al 1991). At birth, this elicits an immediate response in fetal
adrenal secretion of cortisol. Once the neonate is separated from the placenta,
considerable reduction in the metabolic clearance of cortisol occurs, and therefore a
marked increase in adrenal reserve capacity to maintain circulating cortisol levels (Winter
1992).
One of the main metabolic significances of cortisol during the neonatal period is the
maintenance of blood glucose levels through stimulation of hepatic gluconeogenesis,
reduction in extrahepatic protein synthesis, and inhibition of insulin secretion. After birth,
plasma ACTH levels fall rapidly (Winter 1992).
Production of active thyroid hormones is markedly increased in association with the events
of birth. During the first hours after birth, an abrupt 3- to 6-fold increase appears in serum
thyroid-stimulating hormone (TSH) concentration. The thyroid gland is adrenergically
innervated, and the postnatal increase in serum catecholamine concentrations, as well as
the cold-stimulated TSH surge may augment these changes in the T4/T3 ratio of secreted
thyroid hormones. The metabolic significance of the neonatal thyroid hormone surge is not
entirely clear, since neonates with congenital thyroid agenesis do not usually exhibit
impaired environmental adaptation (Polk et al 1992).
The adaptation of the newborn to thermally cooler surroundings requires heat production
from nonshivering thermogenesis. This takes place in brown adipose tissue, with the heat
production governed by signals from the hypothalamus. These signals are relayed via the
sympathetic nervous system and transmitted to the cell as a norepinephrine stimulus
(Nedergaard et al 1992).
In the human neonate the basal metabolic rate increases within the first 2 postnatal days
(Hill et al 1965). The weight loss observed during the same time can be explained mostly
by physiologic fluid loss (Maclaurin et al 1966).
Before birth, about 80% of the energy expended is derived from carbohydrate oxidation.
At birth, the fetus becomes dependent on an external supply of energy and nutritients.
During the first hours of life the amount of energy received is low even when oral food is
supplied quickly. During the first day of life, fat provides between 60 and 70% of energy
expenditure as a result of active lipolysis (Putet 1992).
Fetal glucose utilization during intrauterine life closely matches umbilical uptake. The
majority of the transplacentally derived glucose is oxidized directly, with the remainder
31
directed into hepatic glycogen deposition. At birth, plasma glucose concentrations
decrease to half before 2 to 4 hours of age. This decrease in glucose is even greater in
preterm or SGA infants. At 2 to 3 days of age, plasma glucose concentrations rise to the
normal range. Plasma glucose concentrations are maintained initially by hepatic
glucogenolysis and stimulation of gluconeogenesis, integration of which events is
mediated in great part through catecholamine secretion (Padbury et  al 1992).
 In male, but not in female infants there occurs a postnatal rise in testosterone
concentrations, whereas for concentrations in the early postnatal period, no gender
difference exists in serum estradiol (Winter et al 1976, Sizonenko et al 1978).
2.4.8 Postnatal changes in leptin concentrations
At 6 hours of age, the concentration of circulating leptin in the human newborn infant is of
a similar magnitude to that in cord plasma, but by 2 days, a significant drop in the leptin
plasma concentrations has taken place, and leptin levels remain at this level until one
week of age. Interestingly, the differences observed between AGA, SGA, and LGA infants
in cord plasma disappear by 48 hours (Harigaya et al 1997). At 16 hours of age the
concentration of leptin in the newborn infant is considerably lower than in cord blood, and
remains so at 3 days (Marchini et al 1998). Other studies, too, report a significant
difference between cord plasma and postnatal leptin concentrations (Yura et al 1998,
Matsuda et al 1999, Harigaya et al 1999, Helland et al 1998, Ertl et al 1999). The plasma
leptin levels at 4 and 14 weeks of age are lower than in umbilical cord plasma (Helland et
al 1998).
This reduction in leptin concentration after birth is possibly a result of cessation of the
contribution of placental leptin ( Harigaya et al 1997).
A low leptin concentration shortly after birth may be beneficial to the newborn to enhance
food intake (Harigaya et al 1997, Marchini et al 1998, Yura et al 1998), as an indicator of
which is a negative correlation between cord leptin and weight gain from birth to 4 months
(Ong et al 1999). However, somewhat confusingly, a positive correlation has been found
between  an infant’s weight gain and the magnitude of leptin rise that occurs between 3 to
6 and 30 days of age (Harigaya et al 1999).
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The drop in the infant's body temperature after birth may also contribute to the initial
decrease in leptin production (Trayhurn et al 1995). Fasting and cold-exposure are
accompanied by an increase lipolysis and in levels of free fatty acids. The latter cause a
concentration-dependent inhibition of leptin mRNA levels in cultured mouse adipocytes
(Rentsch et al 1996).
The initially high leptin concentrations may be an important factor in regulation of the non-
shivering thermogenesis in brown adipose tissue: Leptin regulates the function of
uncoupling protein-3 regulated also by thermogenic stimuli, thyroid hormone, and beta3-
adrenergic agonists (Gong et al 1997). Leptin seems to be necessary for this postnatal
recruitment process in brown adipose tissue to start thermogenesis, since in the ob/ob
mouse this process is blunted (Goodbody et al 1982).
The gender difference in leptin concentrations in cord blood at birth is reported in some
(Helland et al 1998, Jaquet et al 1998, Matsuda et al 1997, Gomez et al 1999, Maffeis et
al 1999, Matsuda et al 1999, Ong et al 1999), but not all studies (Schubring et al 1997,
Koistinen et al 1997, Harigaya et al 1997, Tamura et al 1997, Tarquini et al 1999,
Harigaya et al 1999, Yura et al 1998, Marchini et al 1998, Shekhawat et al 1998). In
studies observing postnatal changes in leptin concentration, no mention exists of possible
later development of a gender difference in leptin concentration, in the case that no
difference had existed in cord blood (Harigaya et al 1997, Marchini et al 1998, Yura et al
1998). The gender difference could be a result of the postnatal testosterone surge,
because testosterone has been shown to downregulate production of leptin at both protein
and mRNA levels in human adipocytes (Wabitsch et al 1997). An inverse relationship has
been demonstrated between cord blood leptin and testosterone (Ertl et al 1999). However,
no gender difference in testosterone or estradiol concentrations has been found
concurrent with a gender difference in leptin concentrations in cord plasma (Matsuda et al
1997, Maffeis et al 1999). A confounding factor may be fetal size: Maffei et al (1998) found
lower testosterone concentrations in cord blood of AGA infants than in LGA infants.
In newborn infants, plasma leptin levels are lower during fasting and increase after breast
feeding (Cinaz et al 1999). In human milk, leptin levels correlate with the mothers’ serum
concentrations but are one magnitude of order lower. In nursing rats, leptin is transferred
via milk to the stomach and then into the circulation of the infant rat (Casabiell et al 1997).
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2.5.1 Erythropoietin as an indicator of fetal hypoxia
Erythropoietin (EPO) is produced in the fetal liver, and near term also in the kidney
(Zanjani et al 1989). It regulates the synthesis of bone marrow progenitor cells and
erythrocytes (Zanjani et al 1989), with tissue hypoxia being the main stimulator of
erythropoietin production (Zanjani et al 1989, Widness et al 1986). EPO has also been
shown to be produced by placental trophoblast cells. Whether EPO expression in the
placenta is regulated by hypoxia, and the proportion of placental EPO of all EPO in feto-
placental circulation are thus far unknown (Conrad et al 1996). Since EPO is not stored,
plasma EPO levels are an indicator of rate of EPO synthesis. In response to moderate to
severe tissue hypoxia, a statistically significant increase in erythropoietin concentrations
can be measured within 2 to 4 hours (Widness et al 1986). Increased fetal plasma,
amniotic fluid, and cord plasma EPO concentrations are evident in pregnancies
complicated by pre-eclampsia, intrauterine growth restriction, and maternal diabetes
(Teramo et al 1987, Widness et al 1981, Mamapopulos et al 1994). Both in normal and in
abnormal pregnancies, fetal plasma EPO concentrations correlate well with amniotic fluid
EPO levels before labor (Teramo et al 1987).
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3 OBJECTIVES OF THE STUDY
The aims of these studies were to examine any possible changes in leptin concentrations
taking place during postnatal adaptation. We also studied the effect of maternal diabetes
and pre-eclampsia on fetal and neonatal leptin concentrations, and whether fetal leptin
concentrations are affected by the feto-placental hypoxia which often complicates these
pregnancies.
The specific aims were:
(I) To study three aspects of leptin metabolism during the early postnatal period. First,
we determined whether plasma leptin levels change when the nutrition of the newborn is
transferred from the fetoplacental unit to periodic enteral feeding. Second, we studied
whether plasma leptin concentration in newborn infants is associated with adipose tissue
thickness as determined by ultrasound. Third, we examined the possible development of a
gender difference in leptin levels during the first 3 postnatal days.
(II) To examine whether leptin concentrations are associated with gestational age and
birthweight in infants born before 32 weeks of gestation, especially whether maternal pre-
eclampsia and fetal growth restriction results in altered leptin levels in preterm infants.
(III) To learn whether leptin concentrations of fetuses of diabetic mothers are associated
with fetal hypoxia, as indicated by fetal erythropoietin levels.
(IV) To discover to what extent leptin circulates in free and bound form in newborn infants,
and whether maternal gestational diabets mellitus affects these variables at birth and during
postnatal adaptation.
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4 PATIENTS AND METHODS
Patients and study designs (I, II, III, IV)
4.1.1 Changes in leptin concentration during the early postnatal period (I)
We studied 38 healthy AGA newborn infants (20 male, 18 female; gestational age
39.7±1.3 weeks (mean±SD), range 36.3 - 41.9 weeks) born in the Helsinki City Maternity
Hospital. Birth weight was 3470±552 g (range 2470 - 4630 g). Relative birth weight as
determined by reference to a Finnish newborn population of 74 766 singletons born from
1978 to 1982 (Pihkala et al 1989) was -0.26±1.1 SD, range  -2.0 - +2.0 SD, (Table Ia).
Table I a. Demographic data and plasma testosterone concentrations for the newborns.
Males (n=20) Females (n=18)
At birth At 3 days' age At birth At 3 days' age
Gestational age (weeks) 39.9 ± 1.3 - 39.4 ± 1.2 -
Weight (g) 3675 ± 509a 3469 ± 497b,c 3243 ± 519 3047± 474c
Length (cm) 52 ± 2b - 49 ± 2 -
Relative birth weight
(SD)
0.0 ± 1.0 - -0.6 ± 1.1 -
BMI (kg/m2) 13.8 ± 1.2 13.0 ± 1.1c 13.5 ± 1.2 12.7± 1.1c
Arm circumference (cm) - 11.6 ± 0.8a - 11.0 ± 0.8
Subcutaneous fat (mm) -  4.5 ± 1.3 -  4.9 ± 1.1
Testosterone (nmol/L) 5.8 ± 1.7  2.4 ± 0.9c,d 6.3 ± 3.1 1.4 ± 0.7c
 a
 = P<0.05 vs females,  b = P<0.01 vs females,  c = P<0.001 vs at birth,  d = P<0.001 vs females
Placental weight ranged from 370 to 850 g. Two infants were delivered by Cesarean
section. Two mothers had gestational diabetes treated with diet only. BMI ranged from
11.2 to 16.1 kg/m2 in the newborns, and from 15.8 to 43.8 kg/m2 in the mothers.
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A mixed blood sample was obtained from the umbilical cord at birth, and a venous blood
sample was taken when the infant was 3 days old (mean age 73±9 h, range 60 - 100 h).
Both samples were taken into tubes containing EDTA; these tubes were centrifuged at 3500
rpm for 10 minutes, and plasma was frozen and stored at -20°C until analysis. Birth weight
and length were recorded at birth. At the age of 3 days, the weight was recorded, and the
circumference of the proximal third of the left arm measured with a soft metric measuring
tape. The thickness of subcutaneous adipose tissue at the same site was measured three
times with a 7 MHz linear ultrasound transducer (Acuson 128, Mountain View, CA, USA).
4.1.2 Leptin in preterm infants (II)
We studied 74 preterm infants born in consecutive preterm deliveries in the Department of
Obstetrics and Gynaecology of Helsinki University Central Hospital at GA 24.1 to 32
weeks and birth weight 385 to 2100 g (Table II a). The upper limit of GA was chosen to
minimize the effect of accumulating fetal fat mass as a source of leptin (Carrera et al
1998). GA was determined by ultrasound during the first trimester. Relative birth weight
(weight SD) was determined by reference to a Finnish newborn population of 74 766
singeltons born from 1978 to 1982 (Pihkala et al 1989). Of these infants, 14 were born to
mothers with established proteinuric pre-eclampsia (Table II b). Intrauterine growth
retardation (IUGR, weight  < - 2 SD) affected ten infants (Table II c); of these IUGR
infants, five were born to pre-eclamptic mothers and two infants each were from two triplet
pregnancies without pre-eclampsia. Four pairs of twins and six infants from triplet
pregnancies were included in the study. In 59 cases the mother recieved antenatal
treatment with corticosteroids as two doses of 12 mg betamethasone at a 12-hour interval
more than 12 hours before delivery (mean 4 days 7 hours, SD 3 days 17 hours, range 12
hours - 16 days), (Table II d). BMI was determined as weight(kg)/ length(m)2. Of the
infants, 32 were delivered vaginally and 42 by Cesarean section. Twelve mothers smoked
at least five cigarettes a day. Infants of diabetic mothers and infants with malformations
were excluded. Blood samples from the umbilical vein were taken at birth into EDTA
tubes. The tubes were centrifuged at 1000 x g for 5 minutes, and plasma was frozen and
stored at -20°C until analysis.
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Table II a.      Patient data.               Table II b. Infants with and without maternal pre-eclampsia
pre-eclampsia no pre-eclampsia
 N   74   14 60
Male/Female   37/37   10/4 27/33
Gestational age
(weeks) (SD)
 28.7  (2.4)   29.4  (1.5) 28.5  (2.5)
Weight (g) (SD) 1180  (396)  1048  (221) 1211 (421)
Length (cm) (SD)  37.5  (4.0)   36.5  (2.5) 37.5  (3.9)
BMI (kg/m2) (SD)   8.5  (1.3)     7.7  (0.4)b 8.6  (1.4)
Placenta (g) (SD)   451  (180)    322  (118)b 481  (179)
b p<0.05 vs. infants without maternal pre-eclampsia
Table II c. Infants with and without IUGR                                                Table II d. Infants with and without
exposure to antenatal betamethasone
IUGR no IUGR betamethasone no betamethasone
N 10 64   59 15
Male/Female    5/5 32/32   29/30 8/7
Gestational age
(weeks) (SD)
 29.6  (2.6) 28.5  (2.3)   29.1 (2.1)d 27.0  (2.7)
Weight (g) (SD)  940  (367)c 1218  (389)  1211  (379) 1060  (450)
Length (cm) (SD) 36.0  (4.0) 37.5  (3.7)   38.0  (3.5)d 35.0  (4.0)
BMI (kg/m2) (SD)   7.2  (0.7)c 8.6  (1.3)     8.7  (1.2)d 7.7  (1.4)
Placenta (g) (SD)  358  (157) 465  (180)    456  (191) 429  (130)
 c p<0.05 vs. infants without IUGR                                 d p<0.05 vs infants without exposure to antenatal steroids
38
4.1.3 Increased leptin in fetal hypoxia (III)
We measured leptin and erythropoietin concentrations in cord vein plasma and in amniotic
fluid samples from 25 singleton fetuses of mothers with Type I diabetes mellitus (DM), and
of these 7 had additional proteinuric pre-eclampsia. Mothers’ glycemic control was
evaluated by the glycated hemoglobin-A1C fraction (HbA1C) every 2 to 4 weeks
throughout pregnancy. During the last month of pregnancy the mean HbA1C (SD) was
6.8% (1.2%), (range 4.6 to 9.8%). All infants of this study were delivered at Helsinki
Unversity Central hospital by elective Cesarean section, the indications for which were
complicated maternal DM, contracted pelvis, previous Cesarean section, or fetal
macrosomia. Gestational age corrected by ultrasound examination, ranged from 35.3 to
39.3 weeks, and birth weight from 2690 to 5430 g. The relative birth weight, as determined
by reference to a series of 74 766 Finnish singleton newborns (Pihkala et al 1989), ranged
from -1.1 to 5.6 SD (Table III a).
             Table III a. Patient data
        mean (SD)      range
Males / Females (n)         14/11
Gestational age (weeks)         37.2 (1.0) 35.3 - 39.3
Birth weight (g)        3962  (762) 2690 – 5430
Relative birth weight (SD)           2.0  (1.8)   -1.1 - 5.6
Length (cm)         49.6  (2.6)  44.5 - 53.5
BMI (kg/m2)         15.9  (1.9)  12.2 – 19.7
Head circumference (cm)         35.1  (1.5)  31.5 – 38.0
Apgar score              9  (1)        7 –10
Cord artery Hb (g/l)          154  (16)  120 – 183
Cord artery pO2 (kPa)          2.2  (0.4)    1.1 - 2.9
Cord artery pH         7.24  (0.05) 7.15 - 7.35
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In normal pregnancies we have previously found a median amniotic fluid EPO of
7.5mU/ml (Teramo et al 1987). In our hospital three times this median, ie., amniotic fluid
EPO 22.5 mU/ml, is considered the lower limit of significant fetal hypoxia. Based on this
limit, patients were divided into two groups: hypoxic and non-hypoxic (Table III b).
Table III b. Data on hypoxic (amniotic fluid EPO>22.5 mU/ml) and non-hypoxic
(amniotic   fluid EPO <22.5 mU/ml) infants
hypoxic infants (n=9) non-hypoxic infants (n= 16)
mean (SD) mean (SD)
Gestational age (weeks)  36.5  (0.8)  37.6  (1.0)a
Birth weight (g) 3917  (797) 3987  (766)
Relative birth weight (SD)    2.5 (2.0)    1.7  (1.7)
Length (cm)  49.1  (2.7)  50.0  (2.6)
BMI (kg/m2)  16.1  (2.2)  15.9  (1.9)
Head circumference (cm)  34.5  (1.5)  35.5  (1.5)
Apgar score       9  (0)       9  (1)
Maternal pre-eclampsia (n)       3       4
Maternal HbA1C (%)    7.4  (1.2)    6.5  (1.1)
Cord artery pO2 (kPa)    1.9  (0.5)    2.3  (0.3)a
Cord artery Hb (g/l)    157 (13)    158 (12)
Cord artery pH    7.21 (0.06)    7.25  (0.04)
a
=p<0.05, hypoxic vs. non-hypoxic infants
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Blood samples from the umbilical vein were taken at birth into EDTA tubes, which were
centrifuged at 1000 x g for 5 minutes; plasma was frozen and stored at -20°C until
analysis. Amniotic fluid samples were obtained by amniocentesis performed within 3 days
prior to the operation for the determination of fetal lung maturity, or at Cesarean section.
Amniotic fluid samples were drawn into EDTA tubes and stored at -20°C.
4.1.4 Free and bound leptin (IV)
We studied 13 infants of normal mothers and 13 infants of mothers with gestational
diabetes mellitus (GDM) born in Helsinki City Maternity Hospital. Mean gestational age
(GA), corrected by ultrasound examination, was 40.1 + 1.4 weeks, and birth weight was
3695 + 534 g. Relative birth weight (weight SD) was determined by reference to a Finnish
newborn population of 74 766 singeltons born from 1978 to 1982 (Pihkala et al 1989). The
weight, length, and head circumference were measured at birth, and weight was
measured when the control blood sample was obtained at 3 days of age. BMI was
calculated using birth length both for BMI at birth and for BMI at 3 days of age. None of
the infants presented clinical signs of hypoglycemia at 3 days. They appeared healthy at
birth and at 3 days. No difference existed in clinical parameters between these two groups
(Table IV a).
GDM was diagnosed after a 75-g oral glucose tolerance test according to
recommendations by the Finnish committee on diagnosis and treatment of GDM (Hyvönen
1991, Teramo et al 1993). None of the mothers had pre-eclampsia. In our series, GDM
was treated with diet only, and none of the mothers received treatment with insulin.
Blood samples were drawn at birth from the umbilical vein; at the postpartum age of 3
days (mean 62 + 12 h, range 40-87h) a sample was taken from each infant from a
superficial vein into an EDTA tube. The tubes were centrifuged at 2000 x g for 10 minutes,
and plasma was stored at -20°C until analysis.
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Table IV a. Patient data
All infants Infants of GDM mothers Infants of healthy
mothers
Male/Female 12/14 6/7 6/7
Gestational age (weeks)
Range
40.2 + 1.4
36.9 – 42.4
40.2 + 1.4
36.9 - 41.6
40.3 +1.4
37.1 - 42.4
Birth weight (g)
Range
3693 + 549
2570 – 4740
3757 + 614
2570 – 4500
3630 + 491
2760 – 4740
Birth weight (SD)
Range
0.2 + 1.0
-2.0 - 2.0
0.3 + 1.0
-2.0 - 1.9
0.0 + 0.9
-2.0 - 2.0
Birth length (cm)
Range
50.6 + 2.0
45.0 – 56.0
50.3 + 2.3
45.0 - 53.0
51.0 + 2.4
47.0 - 56.0
BMI at birth
Range
14.3 + 1.2
11.8 -  17.1
14.7 + 1.4
11.8 - 17.1
13.9 + 0.7
12.5 - 15.1
Weight at 3 d of age (g)
Range
3479 + 530a
2545 – 4600
3543 + 565a
2545 – 4245
3415 + 506a
2580 – 4600
BMI at 3 d of age
Range
13.5 + 1.2a
11.7 – 16.3
13.9 + 1.3a
11.7 - 16.3
13.1 + 1.0a
11.7 - 14.7
Weight loss by 3 d age (g)
Range
214 + 87
  25 – 360
214 + 94
  25 + 320
215 + 83
100 – 360
Weight of the placenta (g)
Range
636 + 121
360 – 880
635 + 135
360 – 850
637 + 111
390 – 880
a
=p<0.001 vs. at birth
4.2 Ethics (I, II, III, IV)
All studies were conducted in accordance with the Declaration of Helsinki. Studies I and IV
were approved by the Ethics Committee of the Helsinki City Hospitals. Written informed
consent of the parents was obtained before participation in the study. Studies II and III
were approved by the Ethics Committee of the Department of Obstetrics and Gynecology
of the Helsinki University Central Hospital.
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4.3 Methods (I, II, III, IV)
4.3.1 Blood and amniotic fluid samples (I, II, III, IV)
Samples of mixed (I) or venous (II - IV) cord blood were drawn at birth into EDTA tubes (I-
IV). At a postpartum age of 3 days (mean 73+ 9, range 60-100h, Study I) or mean 62 h +
12 h, range 40-87 h, Study IV, a sample was taken from a superficial vein. Blood was
collected into EDTA tubes and spun for 5 (II, III), or 10 (I, IV) minutes at 3500 (I), 1000
(II,III), or at 2000 g (IV). Plasma was stored at -20oC until analysis (I-IV). Amniotic fluid
samples were drawn into EDTA tubes and stored at -20oC (III).
4.3.2 Anthropometric data (I, II, III, IV)
Birth weight and length were recorded at birth. At the age of 3 days, weight was recorded
(I and IV), and the circumference of the proximal third of the left arm was measured with a
soft metric tape (I).
4.3.3 Measurement of subcutaneous tissue (I)
The thickness of subcutaneous adipose tissue at the same site was measured three times
with a 7 MHz linear ultrasound transducer (Acuson 128). The coefficient of variation of
these three measurements was 6.0%. This method has been validated previously using
computer tomography as a reference standard (Koskelo et al 1991).
4.3.4 Assay of total leptin (I, II, III, IV)
Total leptin was determined by radioimmunoassay in all studies, I-IV (Linco Research, St.
Charles, MO, USA), (Ma et al 1996). The detection limit of this assay is 0.26 µg/L in our
laboratory as determined by calculating two standard deviations (mean of 13 assays) from
the zero reference point. The intra-assay and interassay coefficients of variation at low
concentration (I, II, IV) (2.8 + 0.2 µg/L) are 4.7% (I, II), and 6.1% (IV), and 2.6% (I, II), and
3.0% (IV), respectively, and at medium concentration (I, II, 15.6 µg/L), (IV, 19.6 + 1.4 µg/L)
3.8% (I, II), 6.7% (IV), and 2.2% (I, II, IV), respectively.
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4.3.5 Assay of free leptin (IV)
150 µL of plasma sample was incubated with 150 µL of [125I]leptin (standard amount) at
room temperature at least overnight. Samples were then diluted 1:10 with eluting buffer
(0.1 mol/L sodium phosphate buffer, pH 7.2), and filtered through a Millex-HV 0.45 µm
filter (Millipore). Each cord plasma sample and 3-day sample was treated and eluted in
parallel during the same day.
HPLC analysis was performed by LKB equipment using a 2150 HPLC pump, 2152
controller, and 2212 Helirac (LKB Bromma, Sweden). The column was an Ultropac
Column, TSK G 3000 SW, 7.5X300mm (LKB) equipped with a sample injector with a 100 
µL loop. Elution was performed with degassed 0.1 mol/L sodium phosphate buffer (pH
7.2). Flow-rate was constantly 1.0 mL/min and fraction volume was 1.0 mL. Elution time
was 50 min, so given as 50 fractions per sample. Absorbance at 275 nm was monitored
with a 2151 Variable wavelength monitor (LKB). The radioactivity of the samples was
measured with 1282 Compugamma CS (LKB Wallac, Turku, Finland). In the elution profile
the first peaks shown are bound leptin, and the last peaks represent free leptin (Figure IV).
Peak areas were then estimated from the elution profiles.
Figure IV. The first peaks of the elution profile show bound leptin and the last peaks represent free leptin.
 • = cord plasma;   ∆ = 3-day sample
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Reproducibility of HPLC was performed using [125I]leptin in 1% BSA-phophate buffer.
Variation was 12%. Relative amounts of bound and free leptin were calculated from the
total leptin concentration assayed by RIA for each sample.
4.3.6 Assay of testosterone (I)
Total plasma testosterone concentration was determined with RIA (Orion Diagnostica,
Turku, Finland).
4.3.7 Assay of erythropoietin (III)
EPO was determined by radioimmunoassay (EPO-Trac, Incstar, Stillwater, MN, USA;
Garcia et al 1982).
4.3.8 Statistical methods (I, II, III, IV)
Leptin (I-IV) and EPO (III) concentrations were logarithmically transformed to normalize
distribution when appropriate. Correlation coefficients were calculated with Spearman's test
(I). Analysis of covariance was used to adjust leptin levels for possible confounders(I).
Simple and multiple regression analyses were used (II, III, IV). Patient data are mean, SD,
and range (I, III, IV). Results are mean and SD (I, II), and as median and interquartile
range (II); median and range (III); median + SEM, and range (IV). Wilcoxon’s rank sum
test (I) or the paired T-test (II, IV) served for comparison of paired items. Paired items
such as pre-eclampsia, antenatal steroids, and smoking were categorized as either no=0
or yes=1 (II). Comparison between groups was done with the Mann-Whitney U-test (III,
IV), with a value of p < 0.05 considered statistically significant (I, II, III, IV). Calculations
were done with either the Systat statistical package (Systat, Evanston, IL, USA), (I) or
StatView 4.1 (Abacus Concepts INC., Berkeley, CA, USA), (II, III, IV).
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5. RESULTS (I, II, III, IV)
5.1 Changes in leptin concentration during the early postnatal period (I)
Demographic data for the newborns are given in Table I a. At birth, cord plasma leptin
concentration was 9.7±5.2 µg/L with no gender difference between male (8.6±4.6 µg/L)
and female (10.9±5.6 µg/L, P=0.198) infants (Figure I). In the analysis of covariance, there
was no statistically significant gender difference in leptin levels when adjusted for infant
BMI (P=0.06) or subcutaneous fat (P=0.368). A slight gender difference appeared in leptin
levels when birth weight alone was used as the covariate (log leptin, adjusted least
squares means 0.81±0.28 vs. 1.03±0.26, P=0.021 in male and female infants,
respectively).
Plasma leptin decreased in male (to 1.8±0.4 µg/L, P<0.001) and female (to 2.3±0.8 µg/L,
P<0.001) infants by the third postnatal day (Figure I). At this age, gender difference was
statistically significant (P=0.01).
Figure I. Plasma leptin concentrations in cord blood and at 3 days of age in male (n=20) and female (n=18)
newborn infants. At birth, plasma leptin levels were similar, but decreased both in males and females by the
third postnatal day (P<0.001), with females having higher plasma leptin concentrations (P=0.01).
In male newborns, cord plasma leptin concentration correlated with the circumference of
the arm but not with BMI, subcutaneous fat or birth weight (Table I b). In males at 3 days
of age plasma leptin concentration correlated with none of these parameters (Table I b). In
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female newborns, cord plasma leptin concentration correlated with BMI, subcutaneous fat,
and circumference of the arm, but not with birth weight (Table I b). In 3-day-old females
leptin concentration correlated with BMI, weight and arm circumference (Table I b). The
decrease in leptin concentration in female newborns correlated with their BMI (r=0.63,
P<0.01), subcutaneous fat (r=0.54, P<0.05), and arm circumference (r=0.72, P<0.01); and
in male infants with arm circumference (r=0.50, P<0.05), but not with change in weight in
either group. Neither cord plasma leptin nor plasma leptin at 3 days of age correlated with
maternal BMI in male or female infants.
Table I b. Matrix of Spearman´s correlation coefficients in male (n=20) and female (n=18) newborns.
Males Females
Leptin At birth 3 days At birth 3 days
BMI 0.430 -0.266 0.620b 0.470a
Subcutaneous fat 0.319 -0.049 0.535a 0.427
Birth weight 0.365 -0.063 0.406 0.462
Weight at 3 days 0.310 -0.083 0.457 0.487a
Arm circumference 0.481a -0.028 0.722b 0.493a
aP<0.05, bP<0.01
5.2 Leptin in preterm infants (II)
Immunoreactive leptin was detectable in cord plasma samples from all preterm infants.
Median leptin concentration was 1.01, interquartile range, 0.81-1.43 µg/L. A significant
correlation existed between cord blood leptin and GA (r=0.336, p=0.0037), but not birth
weight (r=0.155), relative birth weight (r=0.211), BMI (r=0.186), placental weight (r=-
0.108), Apgar score (r=0.197), nor cord artery pH (r=-0.104).
Significantly higher leptin was found in infants of pre-eclamptic mothers (median 1.80;
1.11 - 2.08 vs. median 0.93; 0.79 - 1.29 µg/L; p=0.0007), in IUGR infants (median 1.80;
1.34 - 3.04 vs. median 0.93; 0.74 - 1.03 µg/L; p=0.0005), and in those exposed to
antenatal steroids (median 1.18; 0.85 - 1.73 vs. median 0.76; 0.66 - 0.95 µg/L; p=0.02).
Maternal smoking was not observed to affect cord blood leptin concentrations. Infants of
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pre-eclamptic mothers had significantly smaller placentas than other infants [322 (SD 118)
vs. 451 (SD 180) g; p<0.05].
When GA, presence of pre-eclampsia, and exposure to antenatal steroids were included
as independent determinants of leptin concentration in multiple regression analysis, GA
(partial r=0.257, p=0.02), and pre-eclampsia (partial r=0.32, p=0.004) were significantly
and independently associated with leptin, whereas exposure to steroids remained non-
significant  (partial r=0.103, p=0.39).
When IUGR infants and infants born to pre-eclamptic mothers were excluded, simple
regression analysis of the 55 remaining infants revealed significant correlations between
cord leptin and GA (r=0.360, p=0.0069), BMI (r=0.424, p=0.0033), and birth weight
(r=0.487, p=0.0002). In these 55 infants, cord plasma leptin concentration of those
exposed to antenatal steroids (n=41) did not differ from those not exposed, (median 0.94;
0.81 - 1.30 vs. median 0.75; 0.65 -  0.86 µg/L, p=0.09).
5.3 Increased leptin in fetal hypoxia (III)
The cord plasma median concentration of leptin was 9.0 µg/l (range, 3.7 - 135.1µg/l, and
that of EPO 26.2 mU/ml (range, 9.6 - 9263 mU/ml). In amniotic fluid, median concentration
of leptin was 2.2 µg/l (range, 0.7 - 5.7 µg/l), and that of EPO 10.9 mU/ml (range, 1.0 -
1594 mU/ml).
The fetuses of the hypoxic group had significantly higher cord leptin concentrations
(median 36.8; range, 12.5 - 135.1µg/l) than those in the non-hypoxic group (median 16.2;
range, 3.7 - 52.2 µg/l), p=0.0066 (Figure III a). Fetuses of the hypoxic group had lower GA
(p=0.016), and cord artery pO2
 
(p=0.023) at birth (Table III b). Between groups, maternal
HbA1C (p=0.1), Hb (p=0.5), and base excess (BE) (p=0.2) did not differ significantly,
although cord blood pH showed a close to statistically significant difference (p=0.06).
In all fetuses, a significant correlation existed between cord plasma leptin and amniotic
fluid EPO (r=0.727, p=0.0001), cord plasma EPO (r=0.644, p=0.0005, Figure III b),
maternal HbA1C (r=0.612, p=0.0019), and relative birth weight (r=0.399, p=0.049);
whereas negative correlations were found with cord artery pO2 (r=-0.440, p=0.032) and
pH (r=-0.414, p=0.040). In addition, significant correlations existed between amniotic fluid
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EPO and cord plasma EPO (r=0.863, p=0.0001), maternal HbA1C (r=0.646, p=0.0009),
cord artery pO2 (r=-0.644. p=0.0007), and pH (r=-0.558, p=0.0038).
Figure III a. Box and whisker plot of cord plasma leptin concentrations of hypoxic (n=9) and non-hypoxic
(n=16) fetuses at birth
Figure III b. Correlation between umbilical cord EPO(log) and leptin
Neither cord plasma leptin, EPO, nor amniotic fluid EPO correlated with cord hemoglobin
concentration at birth. Nor did amniotic fluid leptin correlate with clinical data or with these
biochemical variables.
In multiple regression analysis with cord plasma leptin as the dependent variable, and
amniotic fluid EPO, cord artery pO2, relative birth weight, maternal HbA1C, and GA as
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independent variables, only EPO (partial r=0.558, p=0.031) remained significantly
associated with cord plasma leptin.
5.4 Free and bound leptin (IV)
Infants of GDM mothers had higher concentrations of total leptin in cord plasma than did
infants of healthy mothers (p<0.05). Likewise, the cord plasma concentrations of free and
bound leptin, as well as the percentage of free leptin, were significantly higher in infants of
GDM mothers (all p<0.05).
A significant decrease from birth to 3 days of age occurred in the concentrations of total,
free, and bound leptin in infants of GDM mothers and infants of healthy mothers (Table IV
b), but the percentage of free leptin remained stable from birth to 3 days of age in both
groups of infants (Table IV b).
Table IV b.  Plasma concentrations of total, free, and bound leptin, and percentage of  free leptin at birth
and at three days of age
Leptin concentration in cord
plasma µg/L + SEM, (range)
All infants Infants of
GDM
mothers
Infants of healthy
mothers
Total 13.2 + 2.1
 (2.4 - 43.8)
17.8 + 3.3a   8.5 + 1.8
Free   7.6 + 1.3
 (1.1 - 27.2)
10.7 + 2.0a   4.4 + 0.9
Bound   5.6 + 0.8
 (1.4 - 16.6)
  7.2 + 1.3a   4.1 + 0.9
Percent of free 55.3 + 1.3
(40.6 - 70.0)
58.7 + 1.7a 51.8 + 1.5
Leptin concentrations at three days
of age µg/L +  SEM, (range)
Total  1.8 + 0.7b
 (0.6 - 3.7)
  2.0 + 0.2b   1.6 + 0.2c
Free  1.0+ 0.1b     
(0.5 - 2.0)
  1.1 + 0.1b   0.9 + 0.1b
Bound   0.9 + 0.1b
 (0.5 - 1.8)
   0.9 + 0.1b   0.9 + 0.1b
Percent of free 55.4 + 1.2
(44.5 - 67.7)
56.5  + 1.6a 50.3 + 1.2
      a
=p<0.05 vs. infants of healthy mothers,  b=p=0.0001 vs. at birth,  c=p=0.0004 vs. at birth
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At 3 days, leptin concentrations in infants of GDM mothers and of healthy mothers were
similar (Table IV b). Infants of GDM mothers tended to have somewhat higher
concentrations of free leptin, but this difference did not reach statistical significance
(p=0.08). However, the percentage of free leptin remained higher in infants of GDM
mothers at 3 days (p<0.05, Table IV b).
In all infants, cord plasma concentrations of total, free, or bound leptin correlated with
none of the clinical parameters presented in Table IV a (data not shown). At 3 days, a
correlation existed between the percentages of free leptin and BMI (r=0.487, p=0.0016). In
multiple regression analysis, with the percentage of free leptin at 3 days as the dependent
variale, and GDM of the mother and BMI at 3 days of age as independent variables, the
percentage of free leptin remained significantly dependent on the GDM of the mother
(partial r=0.432, p=0.028), but not on BMI.
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6 DISCUSSION (I, II, III, IV)
6.1 Changes in leptin concentration during the early postnatal period (I)
Our data confirm the results from previous studies that immunoreactive leptin is present in
cord blood (Hassink et al 1997, Koistinen et al 1997, Sivan et al 1997, Schubring et al
1997, Matsuda et al 1997). Moreover, leptin concentrations in cord blood correlate well
with the adiposity of the newborn as determined directly by measurement of the thickness
of the subcutaneous fat by ultrasound. During intrauterine development, because the fetus
is dependent on the maternal fuel and constituent supply, the presence of a satiety signal
would seem rather paradoxical. The interleukin-6-type cytokine receptor-like structure and
signaling capabilities of the leptin receptor (Bauman et al 1996), and the expression of
messenger-RNA for leptin receptor isoforms in the lungs, liver, and kidneys of human
fetuses (Cioffi et al 1996) raise the possibility that leptin may function as a regulator of
growth during fetal development. Recent data suggesting the placenta as a source of
leptin for the growing fetus (Hassink et al 1997, Masuzaki et al 1997) support the idea of
leptin’s having a physiologic function in the maturation process. At present, however, it is
impossible to distinguish whether the leptin in cord blood is of fetal or placental origin,
although there is a small, albeit significant, arterio-venous difference, with higher leptin
concentrations in blood from the umbilical artery (Schubring et al 1997) suggesting that at
least part of the leptin in the fetoplacental circulation is of fetal origin. This finding has
recently been challenged (Yura et al 1998). Considering the same hormonal mileu shared
by fetus and placenta, and the aforementioned discrepancies in arterio-venous differences
in cord plasma leptin concentrations, it is doubtful whether the use of mixed cord plasma
has had any significant impact on our results.
Leptin concentration decreased markedly during the first 3 postnatal days. The decrease
in infant weight during the same period, which is mostly explained by physiologic fluid loss
(Maclaurin 1966), is unlikely to explain the fall in leptin level, since we found no correlation
between changes in weight and in leptin. The basal metabolic rate increases within the
first 2 postnatal days in the human neonate (Hill et al 1965); growth and development in
the neonatal period becomes dependent on an external energy and constituent supply
while the nutrition of the newborn is being transferred from the fetoplacental unit to
periodic enteral feeding. The postnatal decrease in leptin concentration may thus be a
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physiological adaptation to these profound alterations in  metabolic environment, and may
serve to enhance the newborn’s food intake. According to a recent study, the decrease in
leptin concentrations occurs by 16 hours after birth, and leptin levels remain low until at
least 3 days after delivery (Marchini et al 1998). The mechanisms behind the postnatal fall
in leptin levels remain at present unclear; we cannot exclude the posibility that some of the
decline in plasma leptin concentration reflects the removal of the placental source of
leptin.
There is a well-established gender difference in leptin concentrations in adult humans
(Rosenbaum et al 1996) and in prepubertal children (Hassink et al 1996, Caprio et al
1996), with females showing higher leptin concentrations per unit fat mass. However, data
regarding any gender difference in leptin in newborn infants have been conflicting
(Koistinen et al 1997, Schubring et al 1997, Matsuda et al 1997); a small gender
difference in leptin concentrations was found when 100 newborn infants were studied
(Hassink et al 1997). In our study, the unadjusted leptin levels did not statistically differ
between male and female infants at birth. Recently, Helland et al. suggested that from 18
to 35 weeks of pregnancy, the gender of the infant modifies the increase in maternal leptin
levels: This increase in leptin levels was not significant in women carrying male fetuses.
Moreover, leptin levels were lower in male infants at birth, and the gender difference
became more apparent when leptin/birth weight ratio was analyzed (Helland et al 1998).
Similarily, in our study, female newborns had a higher plasma leptin/birth weight ratio than
male newborns at birth. It is thus possible that the contribution of the placenta in leptin
secretion (Masuzaki et al 1997) may in our study have interfered with the gender
difference in cord plasma leptin levels.
By the third postnatal day, however, a clear gender difference in leptin concentrations had
developed, with higher concentrations in female newborns. In our study, the thickness of
the subcutaneous fat was similar in male and female newborns, and correlations between
plasma leptin at 3 days and weight and arm circumference were evident in female but not
in male newborns’ suggesting that factors other than adiposity, such as the hormonal
milieu, may interfere with the association between leptin and adiposity. No gender
difference exists in serum estradiol concentrations during the early postnatal period,
whereas a postnatal rise in serum testosterone concentrations occurs in male but not in
female newborns (Winter et al 1976, Sizonenko 1978). Adult males show an inverse
relationship between serum leptin and testosterone concentrations that is independent of
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BMI (Nyström et al 1997). A negative correlation between serum leptin and testosterone
concentrations is observed also in adult male IDDM patients (Tuominen et al 1997).
In our study, male newborns had higher plasma testosterone and lower leptin
concentrations than female newborns at 3 days of age, a fact which raises the possibility
that the gender difference in leptin levels may be a result of testosterone downregulating
leptin secretion. Indeed, a recent study has shown this to be the case: testosterone
downregulates leptin production both at the protein and at the mRNA level in human
adipocytes (Wabitsch et al 1997). In leptin-deficient ob/ob mice, leptin treatment corrects
the sterility attributed to insufficiency of hormones at the hypothalamic-pituitary level
(Chehab et al 1996). Moreover, in mice, leptin treatment resulted in earlier maturation of
the reproductive tract than in controls and also in earlier reproduction (Chehab et al 1997).
In humans, an increase in serum leptin levels occurs in both girls and boys before the
appearance of other reproductive hormones, suggesting that leptin may be an important
signal triggering the start of puberty (Mantzoros et al 1997, Garcia-Mayor et al 1997).
Thus, higher leptin levels in females shortly after birth may be physiologically important
and relate to leptin´s role in reproduction. In conclusion, our data suggest that circulating
leptin concentrations correlate with adiposity at birth in female but not in male newborns.
Leptin concentration decreases markedly in both genders by the third postnatal day with a
clear gender difference developing by that time, with higher leptin levels in females. The
postnatal decrease in plasma leptin concentration may be a physiologically feasible
adaptation to extrauterine life.
6.2 Leptin in preterm infants (II)
Our data demonstrate that in preterm infants maternal pre-eclampsia is associated with
increased leptin concentration, and that pre-eclampsia is an independent determinant of
leptin levels. Pre-eclampsia has recently been shown to increase maternal leptin levels,
but no such association has yet been described in the fetus (Mise et al 1998). Reduced
uteroplacental blood flow leading to fetoplacental hypoxia is important in the pathogenesis
of IUGR, eg, in pre-eclampsia (Redman 1991). Mise et al (1998) postulated that the
elevated maternal plasma leptin in pre-eclampsia is caused mostly by augmentation of the
placental production of leptin in response to hypoxia (Mise et al 1998). However, our study
showed no correlation between cord plasma leptin concentration and Apgar score or cord
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artery pH. Similarily, in vitro data indicate that no significant increase in leptin secretion
occurs until 72 hours of hypoxia (Mise et al 1998).
In our study, preterm infants with IUGR, with or without maternal pre-eclampsia, had
higher cord leptin levels than did those experiencing normal growth. This is in contrast to
observations in most but not all studies of full-term infants (Koistinen et al 1997, Harigaya
et al 1997, Tamura et al 1998, Shekhawat et al 1998). Interestingly, in our study, when
infants with IUGR and infants of pre-eclamptic mothers were excluded from the analysis, a
correlation appeared between birth weight and leptin concentration similar to that
observed in term infants. It is thus possible that pre-eclampsia, and IUGR and the
concomitant increase in leptin concentration, may interfere with the association between
leptin and birthweight. The overlap between groups of infants with IUGR and with maternal
pre-eclampsia makes it difficult, however, to differentiate the effects of these two clinical
conditions on leptin metabolism. Our finding of preterm IUGR infants’ having higher leptin
concentrations agrees with a finding by Shekhawat et al 1998, whereas no such
relationship appeared in a study by Jaquet et al 1998. However, those studies did not
examine the possible connection of pre-eclampsia with fetal leptin concentrations (Jaquet
et al 1998, Shekhawat et al 1998). Moreover, in term infants, maturity and fetal fat mass
may interfere with the effects of pre-eclampsia on fetal leptin.
In the preterm infants of this study, placental weight did not correlate with leptin
concentration as it did in term infants (Koistinen et al 1997). In fact, infants of pre-
eclamptic mothers had smaller placentas and increased leptin concentration. This finding
may be explained by the theory that hypoxia augments placental production of leptin (Mise
et al 1998).
Hypoxia and IUGR, the fetal hallmarks of pre-eclampsia, are associated with increased
morbidity (Redman 1991, Kelly et al 1998). The roles of leptin in hematopoiesis, in fetal
erythroid development, and in angiogenesis raise the possibility that relative
hyperleptinemia is part of the fetal adaptation to hypoxia (Cioffi et al 1996, Sierra-
Honigman et al 1998, Mikhail et al 1997, Umemoto et al 1997). In adults, plasma leptin
levels are elevated in survivors of acute sepsis, and leptin has been called a stress-related
hormone (Bornstein et al 1998). If this is true, leptin may play a role in the response to a
severe stress state - such as pre-eclampsia - also in the fetus.
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Shekhawat et al 1998 found use of antenatal steroids to be associated with increased
cord plasma leptin levels in preterm infants. The mean GA in their study was 32 weeks,
and infants of diabetic mothers were included. Unfortunately, no weight data were
available on the infants exposed to antenatal steroids, making the interpretation of their
results difficult. In our infants, we also found an association between the use of antenatal
steroids and high cord plasma leptin. However, when IUGR infants and infants born to
mothers with pre-eclampsia were excluded this correlation disappeared. Moreover, in
multiple regression analysis, because antenatal exposure to steroids was not an
independent determinant of leptin levels, it is therefore possible that the effect of antenatal
steroids on leptin production is primarily dependent on maturity. Thus far, the effects of
corticosteroids on leptin levels are still under dispute also in adults (Kolaczynski et al
1997, Torpy et al 1998).
We found that maturity, defined as GA, is, in preterm infants, a significant determinant of
cord plasma leptin levels. This is in accordance with findings of studies on pre-term and
term infants (Jaquet et al 1998, Koistinen et al 1997, Harigaya et al 1997, Tamura et al
1998, Shekhawat et al 1998), and may be related to the accumulation of adipose tissue in
the fetus during late gestation (Carrera et al 1998). Given the presence of mRNA for leptin
receptor isoforms in the lung, liver, kidneys, and hematopoietic cell lines of human
fetuses, these data suggest that leptin may participate in the regulation of fetal growth and
development (Cioffi et al 1996).
In conclusion, gestational age is an important determinant of cord plasma leptin levels in
preterm infants. Leptin levels are increased in pre-eclampsia and IUGR, which may be
part of fetal physiological adaptation to stress.
6.3  Increased leptin in fetal hypoxia (III)
Our study of diabetic pregnancies demonstrated that fetuses exposed to hypoxic
conditions, as indicated by elevated amniotic fluid EPO concentrations, showed
significantly higher cord plasma leptin concentrations. Moreover, in all fetuses, cord
plasma leptin concentration strongly correlated with amniotic fluid and cord plasma EPO
concentrations.
Our data are in agreement with the findings of Mise et al 1998, who demonstrated that
hypoxia increases placental leptin production. They found in vitro that the rise in leptin
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production in placental cells does not take place until after 72 hours of hypoxia. Because
during hypoxic conditions a significant increase in fetal EPO concentrations can be
observed within 2 to 4 hours (Widness et al 1986), the increased cord plasma leptin,
together with the increased EPO concentrations in both amniotic fluid and cord plasma,
probably reflect chronic or subchronic rather than acute fetoplacental hypoxia.
We found no correlation between amniotic fluid or cord plasma EPO and cord
hemoglobin; this is in accordance with previous studies of infants of diabetic mothers
(Teramo et al 1987, Widness et al 1990), whereas a negative correlation has been
reported between EPO and Hb in normal and Rh-isoimmunized fetuses (Moya et al 1993).
Evidence exists that in infants of diabetic mothers, erythropoiesis is qualitatively abnormal,
resulting in a significant delay in the beginning of β–globin production (Perrine et al 1985),
and in the fetus and in the preterm infant the response of erythropoiesis to EPO differs
from that in the adult (Moya et al 1993, Brown et al 1984). These observations may also,
in part, explain the lack of correlation between cord leptin and hemoglobin.
Both maternal glycemic control in diabetic pregnancies and pre-eclampsia affect cord
plasma leptin concentrations (Shekhawat et al 1998, Mise et al 1998), with amniotic fluid
and cord plasma EPO concentrations  increased in such pregnancies (Teramo et al 1987,
Widness et al 1981, Buescher et al 1998). However, neither the number of pre-eclamptic
mothers nor maternal HbA1C significantly differed between the hypoxic and non-hypoxic
infants. In addition, all infants of this study were delivered by elective Cesarean section,
thus eliminating the possible hypoxia and increase in EPO concentration caused by labor
(Widness et al 1984). Although a correlation existed between cord plasma leptin and cord
blood pH and pO2, in multiple regression analysis only cord plasma EPO remained an
independent and significant determinant of cord plasma leptin concentrations. This
difference between the groups in cord plasma leptin concentrations may be primarily a
result of fetal chronic or subchronic hypoxia.
Leptin has been shown to be involved in angiogenesis and shown to stimulate the
proliferation of myelocytic and primitive hematopoietic progenitor cells (Sierra-Honigmann
et al 1998, Umemoto et al 1997). In vitro data indicate that leptin acts synergistically with
EPO to increase fetal erythroid development (Mikhail et al 1997). Therefore, along with
concomitantly increased EPO concentrations, increased leptin levels may represent a
cooperative and physiologically feasible adaptation mechanism to improve oxygen
transportation capability during periods of decreased oxygen supply. These beneficial
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effects from elevated leptin concentration in the fetus may not be limited to stimulation of
erythroid development and angiogenesis: the cytokine-like properties of leptin receptors
and the better survival of adult septic patients with higher leptin levels has led to
researchers to consider leptin a stress-related hormone (Mikhail et al 1997, Sierra-
Honigmann et al 1998, Umemoto et al 1997, Bornstein et al 1998). Leptin thus may
improve fetal adaptation to such stressful conditions as chronic hypoxia.
We found a positive correlation between cord plasma leptin concentration and maternal
HbA1C, a result suggesting that maternal glucose metabolism may affect leptin
metabolism of the feto-placental unit. This phenomenon is supported by data showing that
insulin increases leptin mRNA (Saladin et al 1995), and data indicating that leptin
secretion in adipocytes is regulated by glucose metabolism (Mueller et al 1998). Mueller et
al demonstrated that the increase in leptin secretion from adipocytes is primarily
dependent on glucose, with the insulin effects’ being secondary. In diabetic mothers, the
expression of leptin mRNA and of protein in placental tissue is elevated (Lepercq et al
1998), implying that the correlation between cord plasma leptin and maternal HbA1C is an
indicator of augmented leptin production in fetal adipocytes and in the placenta.
Human amniotic fluid cells have been shown to secrete leptin into the amniotic fluid
(Masuzaki et al 1997). In our study, amniotic fluid leptin concentrations failed to correlate
with any of the clinical or biochemical parameters, suggesting that secretion of leptin into
the amniotic fluid is independent of these variables.
In conclusion, our study indicates that in Type I DM pregnancies, cord plasma leptin
concentration correlates with severity of fetal hypoxia, as shown by the concentration of
erythropoietin. This phenomenon may reflect one physiological response of the
fetoplacental unit to chronic hypoxia.
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6.4 Free and bound leptin (IV)
Although infants of GDM mothers and those of healthy mothers were similar in terms of
characteristics, the former had higher total, free, and bound cord leptin concentrations.
These data therefore suggest that the differences in leptin metabolism between infants of
GDM and healthy mothers are due to the effect of maternal glucose metabolism. Because
infants of diabetic mothers have higher insulin concentrations in the cord plasma (Lepercq
et al 1998, Persson et al 1999), this, or enhanced glucose metabolism, or both
(Malmström et al 1996, Utriainen et al 1996, Mueller et al 1998) may have stimulated their
leptin secretion in utero to a higher extent. It is also possible that some of the difference in
leptin concentration between infants of GDM and healthy mothers is due to placental
leptin production (Masuzaki et al 1997), because studies have demonstrated placental
leptin protein content to be higher in insulin-treated diabetic than in healthy pregnant
women (Lepercq et al 1998). This finding is in accordance with recent data demonstrating
that cord plasma leptin concentrations are elevated to the same extent in infants of both
GDM and type-1 DM mothers in comparison to concentrations in infants of healthy
mothers (Persson et al 1999). They also concluded that the difference was explained
mostly by enhanced placental leptin production.
In infants of GDM mothers, we observed an increase in free and bound leptin levels at
birth suggesting that maternal GDM increases the concentrations of leptin-binding proteins
in the fetoplacental circulation. This situation appears analogous to that in pregnant
insulin-dependent diabetes mellitus women, who have higher levels of soluble leptin
receptor (Lewandowski et al 1999). Taken together, these data show that insulin or
maternal hyperglycemia, or both, may participate in fetal regulation of free leptin and
leptin-binding protein levels.
In the infants of our study, the concentration of total leptin decreased significantly from
birth to 3 days of age, confirming previous observations (Marchini et al 1998, Helland et al
1998, Yura et al 1998, Matsuda et al 1999, Harigaya et al 1999). Interestingly, our infants’
decrease in free leptin concentration from birth to 3 days was of a magnitude similar to
that in lean adults as a result of 24-hour fasting (Sinha et al 1996), suggesting that, during
the early postnatal period when the infant adapts to extrauterine life, the decrease in
concentration of total and of free leptin may be a physiological reaction to reduce the
inhibitory action of leptin on food intake.
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By 3 days, all differences in concentrations of total and bound leptin between infants of
GDM mothers and healthy mothers disappeared. However, at 3 days the concentration of
free leptin tended to be higher in infants of GDM mothers, although not statistically
significantly. In these infants, at this stage, the percentage of free leptin remained,
however, significantly higher. Although the number of infants studied is comparatively
small, this result is intriguing because it suggests that abnormal glucose metabolism in the
mothers with GDM may have long-term metabolic effects on their offspring. Indeed, it has
been reported that the offspring of mothers with either GDM or type-1 DM are at increased
risk for childhood obesity and for later development of disorders of their glucose
metabolism (Silverman et al 1991, Pettitt et al 1991, Pettitt et al 1993). However, for the
infants of diabetic mothers, further studies are warranted to elucidate to what extent
altered leptin metabolism in utero and during the early postnatal period is predictive of
further development of metabolic disorders. In addition, since cord blood leptin
concentrations are negatively related to weight gain in human infants up to 4 months of
age (Ong et al 1999), it would be interesting to study whether in these infants perinatal
alterations in leptin metabolism influence postnatal growth.
This leptin-binding activity that is compatible with the affinity of the soluble leptin receptor
is higher in prepubertal children than in infants and adults, and appears similar in infants
and adults (Quinton et al 1999). In all infants of our study the percentage of free leptin was
approximately 55%, comparable to that in lean adults (Sinha et al 1996). Free and bound
leptin appear to behave as different compartments, and physiological alterations such as
fasting affect the percentage of free leptin (Sinha et al 1996). Therefore, it is of interest to
note that during the first postnatal days of our study, the percentage of free leptin
remained relatively constant. In adults, percentage of free leptin is related to degree of
obesity and BMI (Sinha et al 1996, Houseknecht et al 1996, Leonhardt et al 1999).
Similarily, although a correlation did exist between percentage of free leptin and BMI at 3
days of age, as indicated by multiple regression analysis, this correlation appeared to be a
function of maternal GDM, rather than of BMI.
In conclusion, infants of GDM mothers have higher cord plasma total, free, and bound
leptin concentrations than do offspring of healthy mothers. By 3 days of age these leptin
concentrations decrease in all infants, and the differences between infants of GDM and
healthy mothers disappear. In contrast, during the early postnatal period the percentage of
free leptin remains unaltered and also remains consistently higher in infants of GDM
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mothers than in those of healthy mothers. These results seem to reflect the difference in
fetoplacental leptin metabolism in GDM mothers at birth, and may be indicative of the
difference persisting in these infants during their postnatal adaptation.
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7 SUMMARY AND CONCLUSIONS
The aims of these studies were to examine changes in leptin concentrations taking place
during postnatal adaptation. In particular we studied whether maternal diabetes and pre-
eclampsia and the abnormal glucose metabolism and hypoxia associated with them
influence leptin concentrations during the fetal and neonatal period.
The main findings and conclusions are:
In female, but not in male, infants, plasma leptin concentrations already correlate with
adiposity at birth. A considerable drop in circulating leptin takes place from birth to 3 days
of age in both female and male infants, and a gender difference in leptin plasma
concentrations develops by this time. This rapid decrease in plasma leptin concentrations
may be a result of the removal of placental leptin production, and the development of a
gender difference in plasma leptin concentrations may reflect differences in hormonal
mileu such as those caused by testosterone, on plasma leptin concentrations. The low
leptin concentration during the postnatal period may be one part of a physiologically
feasible adaptation mechanism.
The decline in leptin concentrations occurs both in infants of healthy mothers and in
infants of mothers with GDM. However, concentrations of free, bound, and total leptin, and
the percentage of free leptin are significantly higher in infants of mothers with GDM at
birth. Moreover, in these infants, the finding that the percentage of free leptin remains
higher suggests that maternal GDM may have long-term metabolic effects on offspring.
Thus, this abnormal maternal glucose metabolism seems to affect leptin metabolism of
the offspring not only in utero, but also during the period of postnatal adaptation. In
addition, the positive correlation of maternal HbA1C with cord plasma leptin suggests that
maternal glucose metabolism augments leptin metabolism of the feto-placental  unit.
In preterm infants, gestational age is an important determinant of cord plasma leptin
levels. Chronic or subchronic feto-placental asphyxia, as indicated either by elevated fetal
erythropoietin levels in term fetuses or by fetal growth restriction in preterm fetuses of pre-
eclamptic mothers, is associated with increased fetal leptin levels. This may be part of the
physiological adaptation to stress such as hypoxia during the fetal period.
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